StreetAccount

Krystal Biotech (KRYS) Full SA coverage

Description Website Edgar Filings Sector: Healthcare Industry: Biotechnology & Drugs Market Cap (USD): 10.40 B

Earnings Profile

Last Earnings Call Transcript
Q2 2026 - 03-Aug-26

Next Earnings Release
02-Nov-26 Pre-Mkt (est 07:00) Conf Call: 02-Nov-26 08:30 (Confirmed) Webcast

Earnings Central

FactSet Consensus	Current Q3 (Sep)	Next Q4 (Dec)	Current Year	Next Year
EPS	$1.82	$1.89	$7.37	$9.02
Revenue	$126.2M	$133.9M	$495.9M	$646.0M

Portfolios Manage

KRYS does not appear in any portfolios.

Today's Move

Price ($)	% Chg	% 30 Day ADV	Options: Impl Move
315.57	+0.6%	21%	10.6%

Avg Tgt: $395.44	13 est.

Upcoming Events

Start Date	End Date	Event
during H2 2026		Company expects to file multiple additional marketing authorization applications for VYJUVEK----Epidermolysis Bullosa dystrophica (including in Switzerland and Australia) VYJUVEK
during H2 2026		Report HALITE-1 study for the treatment of Hailey-Hailey disease (HHD) KB 111
during H2 2026		Interim efficacy data from Phase KYANITE-1 trial in patients with advanced NSCLC KB707
Display All 6 Events

Company News Date Range: 100 Days

Filtered by: All

Records Returned: 20
Related Company News

19-Oct-2026 11:45	^OPTIONS StreetAccount Summary - U.S. Unusual Option Volume: VIX (11.6%) to 17.67; S&P 500 +0.8% to 7,723.71 StreetAccount reports options activity showing unusual volume compared to the 30-day average. The list excludes companies that have reported earnings since the prior trading day's close. 2,972% - RTO (Rentokil Initial $21.15, +0.3%) -- 5,886 contracts vs avg 198 - P/C ratio: 0.00 1,592% - HAS (Hasbro $99.13, +0.4%) -- 10,343 contracts vs avg 650 - P/C ratio: 6.05 - to report earnings before market Oct-20 1,019% - EL (Estée Lauder $105.55, +1.0%) -- 37,256 contracts vs avg 3,657 - P/C ratio: 0.03 915% - SNA (Snap-On $366.60, -0.2%) -- 1,598 contracts vs avg 175 - P/C ratio: 227.29 - to report earnings before market Oct-22 805% - CING (Cingulate $4.38, +0.5%) -- 1,511 contracts vs avg 188 - P/C ratio: 0.15 - continuation of Friday's option volume, scheduled American Academy of Child and Adolescent Psychiatry Meeting event Oct-24 757% - SBLK (Star Bulk Carriers $28.14, +1.3%) -- 13,303 contracts vs avg 1,758 - P/C ratio: 0.00 670% - GLUE (Monte Rosa Therapeutics $10.07, +3.4%) -- 3,462 contracts vs avg 517 - P/C ratio: 0.14 626% - SKE (Skeena Resources $31.69, +0.6%) -- 1,589 contracts vs avg 254 - P/C ratio: 0.00 615% - AMPG (AmpliTech Group $2.45, +2.3%) -- 5,563 contracts vs avg 904 - P/C ratio: 0.00 588% - VTR (Ventas $84.58, -1.5%) -- 1,205 contracts vs avg 205 - P/C ratio: 0.99 - to report earnings after market Oct-27 534% - WU (Western Union $6.15, -0.4%) -- 31,315 contracts vs avg 5,860 - P/C ratio: 0.00 519% - BIOA (BioAge Labs $4.90, +1.2%) -- 1,632 contracts vs avg 314 - P/C ratio: 0.28 482% - ARVN (Arvinas $7.06, +1.2%) -- 1,050 contracts vs avg 218 - P/C ratio: 0.00 470% - M (Macy's $23.89, -0.5%) -- 66,177 contracts vs avg 14,076 - P/C ratio: 32.63 452% - MAIN (Main Street Capital $52.70, -2.1%) -- 2,229 contracts vs avg 493 - P/C ratio: 4.64 - follows guidance Thursday 433% - TVTX (Travere Therapeutics $50.33, +1.5%) -- 2,170 contracts vs avg 501 - P/C ratio: 4.19; scheduled American Society of Nephrology Kidney Week Conference - Abstract: No - SA-OR048 event Oct-24 400% - CDZI (Cadiz Inc $4.06, +4.8%) -- 961 contracts vs avg 240 - P/C ratio: 0.00 - continuation of Friday's option volume 354% - HRB (H&R Block $48.39, -0.6%) -- 2,258 contracts vs avg 638 - P/C ratio: 1.96 328% - REI (Ring Energy $1.38, +0.7%) -- 10,108 contracts vs avg 3,085 - P/C ratio: 0.00 324% - KRYS (Krystal Biotech $318.90, +0.7%) -- 590 contracts vs avg 182 - P/C ratio: 0.00 323% - ARXS (Arxis, Inc. $54.61, +0.9%) -- 523 contracts vs avg 162 - P/C ratio: 0.03 309% - CNP (CenterPoint Energy $39.90, -1.6%) -- 1,276 contracts vs avg 413 - P/C ratio: 0.03 - to report earnings before market Oct-27 308% - ANGX (Angel Studios $3.53, +4.6%) -- 4,030 contracts vs avg 1,307 - P/C ratio: 0.00 303% - GENI (Genius Sports $6.48, +2.0%) -- 4,303 contracts vs avg 1,422 - P/C ratio: 0.01 288% - EVC (Entravision Communications $6.25, -1.1%) -- 1,166 contracts vs avg 404 - P/C ratio: 0.00 288% - BZUN (Baozun $3.79, +1.7%) -- 376 contracts vs avg 131 - P/C ratio: 0.00 287% - CSTM (Constellium $25.54, +0.3%) -- 1,025 contracts vs avg 357 - P/C ratio: 0.01 287% - IRON (Disc Medicine $77.64, +36.6%) -- 7,341 contracts vs avg 2,558 - P/C ratio: 3.47 - after announcing APOLLO Ph3 trial of Bitopertin in EPP met primary endpoint - PPIX reduction -41.4% vs. placebo, p<0.0001; company to resubmit NDA by year-end 276% - AESI (Atlas Energy Solutions $9.63, -2.1%) -- 902 contracts vs avg 327 - P/C ratio: 0.01 273% - XRAY (Dentsply Sirona $8.44, -1.6%) -- 2,076 contracts vs avg 759 - P/C ratio: 0.02 Click here to view / receive alerts for Unusual Options Volume Related: AESI, AMPG, ANGX, ARVN, ARXS, BIOA, BZUN, CDZI, CING, CNP, CSTM, EL, EVC, GENI, GLUE, HAS, HRB, IRON, KRYS, M, MAIN, REI, RTO, SBLK, SKE, SNA, TVTX, VTR, WU, XRAY...(more)	show story hide story
15-Oct-2026 07:03	KRYS Krystal Biotech announces clinical update supporting initial proof of concept for KB113 ($330.69) Krystal Biotech announced a clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in the treatment of basal cell carcinomas (BCCs) in patients with Gorlin syndrome: Broad antitumor responses were detected in all three Gorlin syndrome patients treated with KB113, with over 80% of assessed BCC lesions reducing in size; Responses were observed in both injected and non-injected lesions, including substantial regression in lesions that were not directly injected with KB113, consistent with an abscopal effect; and Complete clearance of an injected lesion was also confirmed histologically for each of the three patients treated with KB113. Gorlin Syndrome Pilot Study Clinical Results KB113 is the low dose of intratumoral KB707 that showed promising early efficacy signals in patients with BCC in the company's OPAL-1 Phase 1/2 study, an open label, multicenter, dose escalation and expansion Phase 1/2 study in patients with injection-accessible solid tumors. The Gorlin Syndrome Pilot Study was a multicenter, single-arm, open label study designed to evaluate the safety and preliminary efficacy of KB113 for the treatment of BCCs in patients with Gorlin syndrome. Three adult patients with Gorlin syndrome were enrolled in the study. All three patients received six doses of up to 2 mL of 108 PFU/mL KB113 over a period of 14 weeks, with the first two doses spaced two weeks apart followed by dosing once every three weeks. Landmark lesions, defined as facial BCCs ≥5 mm in diameter or non-facial BCCs ≥9 mm in diameter, were identified by the investigator and visually assessed for clinical regression throughout the 14-week treatment period and again 30 days after the final dose using a pre-specified, investigator-assessed 5-point clearance scale. The scale categorizes each lesion by magnitude of regression. Only landmark lesions were eligible for injection with KB113. The investigator selected which landmark lesions to inject, irrespective of anatomical location, and determined the injection volume for each lesion based on its clinical presentation. Additional details on the OPAL-1 study can be found at www.clinicaltrials.gov under NCT identifier: NCT05970497. Regression of landmark lesions was observed as early as two weeks after initiation of treatment, with responses broadening and deepening over time. At the final assessment conducted 30 days after last dose, over 80% of all assessed landmark lesions had regressed. Over half of all landmark lesions demonstrated greater than 50% clinical regression, and a subset demonstrated at least 90% clinical regression, as assessed using the investigator-assessed 5-point clearance scale. Substantial regression was observed in lesions that had never been directly injected, providing preliminary evidence of an abscopal effect. To further assess clinical regression, one injected lesion from each patient that had achieved at least 90% clinical regression was biopsied. All three biopsied lesions demonstrated histologically confirmed complete response, with no evidence of residual tumor tissue. Consistent with prior experience in the low dose escalation cohort of OPAL-1, KB113 was well tolerated by all three patients enrolled in the Gorlin Syndrome Pilot Study. All reported adverse events were mild or moderate in severity, transient, and resolved during the study. The company has initiated discussions with the FDA regarding the advanced clinical development of KB113 for the treatment of Gorlin syndrome. The company will provide an update on its clinical development plans following alignment with the FDA. Reference Link: Press release	show story hide story
24-Sep-2026 16:47	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to moderately higher overall on Thursday. Decliners narrowly outnumbered advancers on the XLV, versus a highly positive breadth around the open. Healthcare +0.65% vs S&P 500 (0.02%). Major health groups ended widely split on the session. MedTech group today's primary source of upside, behind two specific catalysts. First the diagnostic subgroup received support overnight from the FDA Adcom on Galleri MCED test. GRAL +15.4% also a tailwind for the broader space. Second, TWST +16.1% following pre-open comments by Leerink analyst Puneet Souda, highlighted the Bio AI opportunity in Twist Bio, in the wake of yesterday's AI for Biology comments from the CEO of Anthropic. Timely Investor Day for CRL +6.2%, third-best on the XLV. ILMN +7.3% today's top advancer on the XLV; DVA (4.6%) quietly today's top decliner. Biotech shares choppy amid the ongoing yield curve worries. XBI +0.55% managed a bounce-back from Wednesday's sell-off. Senator Cassidy and the Senate HELP Committee grilled the nominee for FDA Commissioner, who believes that all FDA approved vaccines have been proven safe and effective, including the MMR vaccine. Dr Overton's uphill battle for confirmation continues. Trial results in Alzheimer's Disease Psychosis highlight the biotech newsflow. ACADIA Pharmaceuticals announced that its RADIANT study missed on the primary endpoint. Company removing the lower 30mg dosage arm, and amending the ongoing trials. Post-close on Wednesday, an FDA advisory committee voted in support of the Galleri MCED test. Yesterday, Healthcare equities finished broadly lower and roughly inline overall. Biotech group an outlier with XBI (4.12%) - worst one-day decline since 2-Jun-2026. Just five modest gainers on the Biotech ETF, which erased all weekly gains and more. Sector newsflow remained very quiet. No specific catalyst identified for the pullback, but rate worries a plausible excuse. An FDA advisory committee for Galleri test for MCED raised questions about efficacy. Shares of GRAL halted throughout the day. Macro Stocks bounced off session lows following Reuters report US and Iran exploring phased deal to end conflict, starting with reopening Strait of Hormuz in exchange for lifting US economic blockade and unfreezing assets, though sequencing remains an obstacle. Oil, short-end Treasury yields retreated from highs (though still elevated). However, long end of the curve remains under pressure with yields near session highs after Treasury bought just $4.08B of 20-30Y debt in today's buyback (below the $6B max), compounding growth/inflation scrutiny. Short end seemingly facing a floor given hawkish Fed pricing (70% chance of an October hike, ~37 bp through year-end, both up slightly d/d). AI sentiment somewhat cautious as focus shifted to regulatory bottlenecks, financing risks after ORCL declared force majeure on delayed New Mexico data center project. Other areas of focus include few concrete takeaways from today's Trump/Xi summit, another META rally (Connect, Muse momentum), AI product discounting (AMZN), CTA positioning suggesting downside risk, ramping buyback blackout. Notable Gainers +108.4% SRZN (Surrozen): small-cap biotech; read-through from MRK trial results +16.1% TWST (Twist Bioscience): best performer on XBI; Leerink comments on Anthropic developments; shares +481% YTD +15.4% GRAL (GRAIL, Inc.): following FDA panel votes on Galleri PMA +13.0% CDNA (CareDx): DX sympathy to GRAL; 52-week high +11.2% TXG (10X Genomics): DX sympathy to GRAL; shares +416% YTD +10.8% VCYT (Veracyte): DX sympathy to GRAL +9.2% BLLN (BillionToOne): DX sympathy to GRAL +7.3% ILMN (Illumina): DX sympathy to GRAL; 52-week high; best performer on XLV +7.0% MRNA (Moderna): shares +26% WTD; 52-week high +6.2% CRL (Charles River Laboratories): Investor Day; LST strength +6.2% ARCT (Arcturus Therapeutics): trial results in OTC deficiency; upgraded at Citi +6.0% RVTY (Revvity): LST strength +4.6% NTRA (Natera): DX sympathy to GRAL; 52-week high +4.5% A (Agilent Technologies): LST strength; 52-week high +2.7% LLY (Eli Lilly): FDA approves Onswik, once-weekly basal insulin Notable Decliners -12.8% ACAD (Acadia Pharmaceuticals): trail results in Alzheimer's Disease Psychosis (ADP); worst performer on XBI -12.6% SGMT (Sagimet Biosciences): resumed sell at Goldman Sachs -11.8% VKTX (Viking Therapeutics): secondary offerings (common stock and convertible notes) -10.4% QURE (uniQure NV): on >3X average daily volume -9.9% VOGX (Vogenx, Inc.): recent IPO; shares (26%) WTD -8.5% CGEM (Cullinan Therapeutics): pipeline updates; shares were (22%) yesterday -4.6% DVA (DaVita): worst performer on XLV; on below average volume -3.5% UTHR (United Therapeutics): initiation at Goldman Sachs Twist Biosciences trading higher; Leerink comments on Anthropic and AI for Biology TWST +11.4% and leading gainer on the XBI around midday Thursday. Move at least in part due to comments made by Leerink Partners (outperform rating) highlighting Twist as the single most important beneficiary of Bio AI efforts, as Anthropic CEO mentioned yesterday. Firm also bullish on the LST space more broadly. Grail's successful Adcom at FDA lifts diagnostic space GRAL FDA panel votes to support PMA approval of Galleri MCED test. The advisory committee voted 10-0 on safety, 6-4 on efficacy, and 7-2-1 on benefit-risk profile. Merck clinical results in DME deliver mixed review of Wnt pathway MRK announced topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating remigromig in adults with DME. Study demonstrated non-inferiority to active control ranibizumab (Lucentis, ROP.SW) in BCVA at week 52. Read-across to SRZN which is developing Wnt pathway antibodies for DME and other retinal disease. Trial results in SMID-cap biotech ACAD announced topline results from the phase 3 RADIANT study evaluating remlifanserin for the treatment of Alzheimer's Disease Psychosis (ADP). Study demonstrated evidence of dose effect - with 60mg once daily. Narrowly missed the primary endpoint. Company implementing protocol amendments, including dropping the 30mg dosage arm, and the phase 3 studies will continue. Detailed data will be presented at CTAD in November. KYTX announced topline results from KYSA-8 (one-year data) in stiff person syndrome, and longer-term data from the phase 2 portion of KYSA-6, a registrational study for miv-cel in gMG. CEO comments: "The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cel's potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases." ARCT announced interim phase 2 results from study of ARCT-810 in ornithine transcarbamylase (OTC) deficiency. Company also announced LUNAR 2.0, its next-gen mRNA delivery platform. Also disclosed the acquisition of myNEO. Terms not disclosed. Stock upgraded in reaction FDA approves Merck/Eisai combo for 2L+ ccRCC Ten days ahead of the 4-Oct PDUFA goal date, the FDA approved the sNDAs filed for Welireg (MRK) and Lenvima (4523.JP), for a new combination treatment for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. (EXEL, RCUS) Notable research in Healthcare today Biotech: ARCT upgraded to buy from neutral at Citi (Yigal Nochomovitz), follows phase 2 results. Target increased to $20 from $8 or approx. 50% upside. (FactSet average PT $23; range $9-41) EPRX initiated outperform at Wedbush Securities (Martin Fan), target is $17 or approx. 109% upside. MGTX initiated neutral at Goldman Sachs (Andrea Newkirk), target is $16 or approx. 36% upside. (FactSet average PT $28; range $16-50) NTHI initiated buy at Roth Capital (Jonathan Aschoff), target is $20 or approx. 521% upside. (FactSet average PT $17; range $13-20) QNCX initiated buy at Rodman & Renshaw (Seema Sheoran), target is $70 or approx. 132% upside. TTRX initiated buy at Lucid Capital Markets (Dev Prasad), target is $24 or approx. 78% upside. UTHR initiated sell at Goldman Sachs (Andrea Newkirk), target is $321 or approx. 34% downside. (FactSet average PT $638; range $321-725) Goldman Sachs (Andrea Newkirk) also resumed seven biotech stocks with buy ratings (INSM, IOVA, JAZZ, KRYS, MDGL, RVMD, TARS), four with neutral ratings (ABCL, ALKS, ARWR, KOD) and one sell (SGMT) MedTech: MMED initiated buy at Truist (Richard Newitter), target is $29 or approx. 41% upside. (FactSet average PT $26; range $21-29) TWST Leerink Partners analyst Puneet Souda highlights Twist as the single-most important beneficiary of AI for Biology. Also sees upside for LST more broadly. Post-close news Regulatory: PRME announces FDA clearance of IND for phase 1/2 trial with PM647 in AATD. Shares trading +14.0% in the after-hours Corporate: STAA announces $50M share repurchase authorization. Shares trading +2.0% in the after-hours Research: LMRI initiated overweight at Keybanc (Matthew Gillmor), target is $18 or approx. 82% upside. (FactSet average PT $18; range $13-23) Shares trading +1.2% in the after-hours On Deck: Syndicate calendar / IPO pricing Thu 24-Sep (post-close) +ADRX Adarx Pharmaceuticals - S-1A Regulatory on Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY eligible for royalties) on Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB eligible for royalties) Peek Ahead to next week Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Syndicate / IPO pricing: +OURA Oura Ring - S-1A StreetAccount Healthcare Reads FDA nominee voices support for vaccines at Senate hearing scrutinizing Trump administration efforts (24-Sep) AP US CDC confirms first measles-related death of 2026, does not disclose state (23-Sep) Reuters Nominee to lead FDA aims to speed up medical research, combat China's rise (23-Sep) STAT News Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA (22-Sep) STAT News (opinion) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4523.JP, A, ABCL, ACAD, ALKS, ARCT, ARWR, BIIB, BLLN, BMY, CAMP, CDNA, CGEM, CI, CRL, DVA, EGTX.SS, EPRX, EXEL, GRAL, ILMN, INCY, INSM, IOVA, JAZZ, KOD, KRYS, KYTX, LLY, LMRI, MDGL, MGTX, MIRM, MMED, MRK, MRNA, NTHI, NTRA, PRME, QNCX, QURE, RCUS, ROP.SW, RVTY, SGMT, SRZN, STAA, TARS, TTRX, TWST, TXG, UTHR, VCYT, VKTX, VOGX, +ADRX, +OURA...(more)	show story hide story
24-Sep-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Trial results in Alzheimer's Disease Psychosis highlight the biotech newsflow. ACADIA Pharmaceuticals announced that its RADIANT study missed on the primary endpoint. Company removing the lower 30mg dosage arm, and amending the ongoing trials. Shares of ACAD (5%) in the pre-market. Post-close on Wednesday, an FDA advisory committee voted in support of the Galleri MCED test. Shares of GRAL resumed trading higher by as much as +10%, currently down (8%) in the pre-market. Today, Senator Cassidy and the Senate HELP Committee hold hearing on the FDA Commissioner nomination (10:30ET). Yesterday, Healthcare equities finished broadly lower and roughly inline overall. Biotech group an outlier with XBI (4.12%) - worst one-day decline since 2-Jun-2026. Just five modest gainers on the Biotech ETF, which erased all weekly gains and more. Sector newsflow remained very quiet. No specific catalyst identified for the pullback, but rate worries a plausible excuse. An FDA advisory committee for Galleri test for MCED raised questions about efficacy. Shares of GRAL halted throughout the day. Macro S&P futures are down (0.6%) on Thursday morning. Bond yield backup still the big story (though yields off worst levels). Market now pricing in a 70%+ probability of another Fed tightening in October and just over 35 bp of rate hikes through end of the year. Usual suspects in play though some heightened focus on growth vs inflation. Spike in bond vol another area of scrutiny, along with adverse spillover effects for small caps. US-China trade truce extended by just two months and no additional details heading into Trump-Xi meeting today. Oil higher for a second straight session as lack of diplomatic traction at UN seems to be overshadowing latest headlines about Saudi efforts to boost shipments through SoH. AI headlines have revolved around the hardware announcements at the META Connect event, agentic proliferation moving pieces/debates, recent surge in discounting for AI products (AMZN latest), higher financing costs (SoftBank) and build-out as biggest economic bet in US history. Pre-market trading update Trading higher +69.3% SRZN small-cap biotech; read-through from MRK trial results +10.9% KYTX trial results in gMG; call at 8ET +6.5% ARCT trial results in OTC deficiency; upgraded at Citi in reaction +1.0% NKTR on light volume; shares (14%) WTD amid litigation Trading lower -12.9% VKTX secondary offerings (common stock and convertible notes) -8.1% GRAL resumed following FDA panel votes on Galleri PMA -5.2% ACAD trail results in Alzheimer's Disease Psychosis (ADP) -2.1% MRNA shares are up +18% WTD -2.0% UTHR initiation at Goldman Sachs -1.7% SGMT resumed sell at Goldman Sachs Pharma Trial results: MRK announced topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating remigromig in adults with DME. Study demonstrated non-inferiority to active control ranibizumab (Lucentis, ROP.SW) in BCVA at week 52. Read-across to SRZN which is developing Wnt pathway antibodies for DME and other retinal disease. Biotech Trial results: ACAD announced topline results from the phase 3 RADIANT study evaluating remlifanserin for the treatment of Alzheimer's Disease Psychosis (ADP). Study demonstrated evidence of dose effect - with 60mg once daily. Narrowly missed the primary endpoint. Company implementing protocol amendments, including dropping the 30mg dosage arm, and the phase 3 studies will continue. Detailed data will be presented at CTAD in November. Conf. call at 8:00ET KYTX announced topline results from KYSA-8 (one-year data) in stiff person syndrome, and longer-term data from the phase 2 portion of KYSA-6, a registrational study for miv-cel in gMG. CEO comments: "The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cel's potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases." Conf. call at 8:00ET ARCT announced interim phase 2 results from study of ARCT-810 in ornithine transcarbamylase (OTC) deficiency. Company also announced LUNAR 2.0, its next-gen mRNA delivery platform. Also disclosed the acquisition of myNEO. Terms not disclosed. Stock upgraded in reaction Regulatory: GOSS announced the submission of seralutinib NDA for the treatment of PAH. Litigation: RGNX and UPenn announce settlement agreement with Sarepta Therapeutics (SRPT) regarding patent litigation over Elevidys IP. Sarepta will pay $39M to REGNEXBIO within ten days. All litigation between the parties terminated. Research: ARCT upgraded to buy from neutral at Citi (Yigal Nochomovitz), follows phase 2 results. Target increased to $20 from $8 or approx. 50% upside. (FactSet average PT $23; range $9-41) EPRX initiated outperform at Wedbush Securities (Martin Fan), target is $17 or approx. 109% upside. MGTX initiated neutral at Goldman Sachs (Andrea Newkirk), target is $16 or approx. 36% upside. (FactSet average PT $28; range $16-50) NTHI initiated buy at Roth Capital (Jonathan Aschoff), target is $20 or approx. 521% upside. (FactSet average PT $17; range $13-20) QNCX initiated buy at Rodman & Renshaw (Seema Sheoran), target is $70 or approx. 132% upside. TTRX initiated buy at Lucid Capital Markets (Dev Prasad), target is $24 or approx. 78% upside. UTHR initiated sell at Goldman Sachs (Andrea Newkirk), target is $321 or approx. 34% downside. (FactSet average PT $638; range $321-725) Goldman Sachs (Andrea Newkirk) also resumed seven biotech stocks with buy ratings (INSM, IOVA, JAZZ, KRYS, MDGL, RVMD, TARS), four with neutral ratings (ABCL, ALKS, ARWR, KOD) and one sell (SGMT) Life Science & MedTech Regulatory: GRAL FDA panel votes to support PMA approval of Galleri MCED test. The advisory committee voted 10-0 on safety, 6-4 on efficacy, and 7-2-1 on benefit-risk profile Corporate: CRL reaffirms FY26 guidance ahead of Investor Day meeting (9:00ET) Research: MMED initiated buy at Truist (Richard Newitter), target is $29 or approx. 41% upside. (FactSet average PT $26; range $21-29) Services & Hospitals Regulatory: CMS initiates NCA for Screening of HCV in adults. At the request Quest Diagnostics and others, the agency will re-evaluate the 2014 NCD. (DGX, LH, GILD, ABBV) On Deck: Conferences (cont.): Bernstein Healthcare Forum (Sep 23-24) (cont.): Stifel Immunology & Inflammation Virtual Forum (Sep 23-24) Regulatory Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) on Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY eligible forroyalties) on Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB eligible for royalties) Corporate CRL hosting Investor Day (9:00ET) INFU hosting Investor Update call (14:00ET) Syndicate calendar / IPO pricing Thu 24-Sep (post-close) +ADRX Adarx Pharmaceuticals - S-1A Peek Ahead to next week Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Sun 4-Oct: FDA PDUFA for MRK/Eisai Welireg/Lenvima sNDA Syndicate / IPO pricing: +OURA Oura Ring - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4523.JP, ABBV, ABCL, ACAD, ALKS, ARCT, ARWR, BIIB, BMY, CAMP, CI, CRL, DGX, EGTX.SS, EPRX, GILD, GOSS, GRAL, INCY, INFU, INSM, IOVA, JAZZ, KOD, KRYS, KYTX, LH, MDGL, MGTX, MIRM, MMED, MRK, MRNA, NKTR, NTHI, QNCX, RGNX, ROP.SW, SGMT, SRPT, SRZN, TARS, TTRX, UTHR, VKTX, +OURA...(more)	show story hide story
24-Sep-2026 06:06	Goldman Sachs initiates MGTX, UTHR; resumes ABCL, ALKS, ARWR, others Initiated: MeiraGTx Holdings (MGTX $11.75) initiated neutral with $16 target, 36% upside (FactSet average target $27.75; range $16-50) United Therapeutics (UTHR $489.42) initiated sell with $321 target, 34% downside (FactSet average target $637.92; range $321-725) Assumed: Insmed (INSM $118.34) resumed buy; target is $188, 59% upside (FactSet average target $199.04; range $169-243) Iovance Biotherapeutics (IOVA $10.19) resumed buy; target is $15, 47% upside (FactSet average target $10.70; range $6-15) Jazz Pharmaceuticals (JAZZ $234.88) resumed buy; target is $337, 43% upside (FactSet average target $296.20; range $229-337) Krystal Biotech (KRYS $341.75) resumed buy; target is $441, 29% upside (FactSet average target $392.11; range $284-474) Madrigal Pharmaceuticals (MDGL $513.02) resumed buy; target is $704, 37% upside (FactSet average target $682; range $543-962) Revolution Medicines (RVMD $190.74) resumed buy; target is $267, 40% upside (FactSet average target $253.92; range $179-320) Tarsus Pharmaceuticals (TARS $74.29) resumed buy; target is $116, 56% upside (FactSet average target $100; range $84-116) AbCellera Biologics (ABCL $12.31) resumed neutral; target is $13, 6% upside (FactSet average target $16.67; range $9-30) Alkermes (ALKS $42.13) resumed neutral; target is $50, 19% upside (FactSet average target $56.72; range $38-83) Arrowhead Pharmaceuticals (ARWR $66.96) resumed neutral; target is $74, 11% upside (FactSet average target $107.83; range $74-126) Kodiak Sciences (KOD $31.52) resumed neutral; target is $36, 14% upside (FactSet average target $64; range $36-85) Sagimet Biosciences (SGMT $10.42) resumed sell; target is $7, 33% downside (FactSet average target $27.62; range $7-56) Analyst is Andrea Newkirk Related: ABCL, ALKS, ARWR, INSM, IOVA, JAZZ, KOD, KRYS, MDGL, MGTX, RVMD, SGMT, TARS, UTHR...(more)	show story hide story
10-Sep-2026 16:35	KRYS Transcript Intelligence: Krystal Biotech at Cantor Global Healthcare Conference ($345.55 -$2.54) Conference Presentation Summary (Presentation Time: 10-Sep-26 15:55 ET): VYJUVEK revenue is expected to keep rising, but more gradually than in the initial U.S. launch, as new patient demand continues while utilization among longer-treated patients moves closer to a steadier pattern. VYJUVEK’s next growth leg is expected to come from Europe and Japan over the next 12 to 18 months, with Europe viewed as at least comparable to the U.S. opportunity and potentially larger on patient volume despite country-by-country launch and pricing complexity. European reported sales may remain distorted until pricing is finalized in key markets, because accrual accounting in countries such as Germany and France can temporarily mute the revenue picture even as underlying demand grows. Krystal expects upcoming pipeline readouts over the next few months to year to test whether it can move from a single-product story to a multi-product genetic medicines company over the next few years. The company said its profitable, fully integrated model should allow it to keep advancing much of the pipeline without needing to raise capital, reducing expected shareholder dilution risk. Hailey-Hailey is emerging as a potentially important next dermatology program, with early work suggesting substantial unmet need and a patient population at least roughly twice dystrophic epidermolysis bullosa; an initial study is expected to finish by year-end and could support FDA discussions on a registrational path. The aesthetics program is intended to resume next year, but Krystal expects it will need a partner for development and commercialization because current priorities are centered on multiple registrational rare-disease programs. The ocular pipeline is being pushed directly into registrational development because the company believes prior biology, pharmacokinetic work, and platform manufacturing advantages support moving faster, with commercial preparation likely to depend on whether the product shows meaningful differentiation versus OXERVATE. In neurotrophic keratitis, Krystal’s commercial strategy would rely on showing a differentiated profile, particularly on efficacy, safety, and once-daily dosing versus OXERVATE’s six-times-daily regimen, with Europe and Japan representing potentially less competitive expansion markets if the trial succeeds. The lung cancer program remains active, with durable responses in some heavily pretreated patients supporting continued development, but later-stage advancement is expected to require a partner. This summary was created with GenAI, optimized by StreetAccount. Early transcripts may contain phonetic spellings. Reference Link: Transcript	show story hide story
14-Aug-2026 08:23	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Capricor Therapeutics reported Q2 results, and provided an update on the regulatory review of deramiocel on the earnings call. Subsequent to the negative Adcomm meeting, which focused on the secondary endpoint, company discussed with FDA an amendment to their BLA submission, and FDA expressed an openness to review and possibly extend the PDUFA date beyond August 22nd. Stock upgraded in reaction. Shares of CAPR +98% in the pre-market. Pfizer and Vaccine developer Valneva announced that EMA has validated their MAA submission for Lyme Disease vaccine LB6V. ADRs for VALN trading +30% in the pre-market. Yesterday, Healthcare equities finished mixed to little changed overall. Decliners narrowly outnumbered advancers on the XLV. Healthcare (0.05%) vs S&P 500 +0.65%. Sector newsflow remained very quiet outside of the long tail of SMID-cap biotech earnings, plus a handful of rating changes. Macro S&P futures are little changed on Friday morning. Quiet end to a fairly quiet week outside of the inflation data. OpenAI's reported $40B annual revenue run rate and AMAT earnings/outlook commentary the latest bullish talking points around AI (though latter up against a high bar). FT report also highlighted the price war among the frontier models amid competition from China. Some focus on higher oil amid US preview of new measures intended to cripple Iran economically. Elevated US borrowing rates another area of scrutiny in the financial press despite the move lower in rates this week. BoJ also in the headlines again with Reuters highlighting increased likelihood of a September rate and a potentially faster pace of tightening to follow. Next week looks fairly quiet with retail earnings, July FOMC minutes and flash PMIs the highlights. Last week of August more important given NVDA earnings and Warsh speech at Fed's Jackson Hole conference. Pre-market trading update Trading higher +98.2% CAPR announced plan to submit amendment to BLA, FDA open to review and potential PDUFA date extension; upgraded at Cantor Fitzgerald +30.1% VALN EMA validates MAA for Lyme Disease vaccine (w/PFE) +25.4% HTFL earnings +25.0% ETON earnings +24.2% VERA Wells Fargo comments on FDA review document +10.0% NERV upgraded at Jefferies +3.2% FRNM initiation (low volume) +2.3% BSX on 98K shares +0.1% LNTH FDA approves imaging agent TAUKLARIFY Trading lower -14.3% SPRY earnings, CSU timeline update -12.4% IPHA secondary offering priced; business update call at 8ET -0.1% PFE sympathy to VALN Pharma Regulatory: BMY Post-close on Thursday, the FDA announced it has granted Accelerated Approval (AA) for Zenbexus (iberdomide) in combination with Darzalex Faspro and dexamethasone for adults with r/r multiple myeloma. The PDUFA goal date for the NDA was 17-Aug-2026. Media report / regulatory: Peptide Critic published independent laboratory findings from four sealed vials of research compounds purchased over the counter at a Brooklyn smoke shop -- it could not confirm retatrutide (LLY) or NAD+ in any sample. Biotech Earnings: CAPR reported Q2 results including cash & equivalents $237.9M at 30-Jun - seen as sufficient for the next 12 months. Despite negative outcome for deramiocel Adcomm, Company working towards PDUFA goal date of 22-Aug. On the call: management stated that FDA is 1) open to them submitting an amendment to the BLA and 2) extending the PDUFA goal date. SPRY reported Q2 results including cash & equivalents $143.8M, and with revised cash-based expense plan, expects to reach break-even cash flow by the end of 2027. Regulatory: VLA.FP (VALN) announced that EMA has validated the MAA for Lyme Disease vaccine LB6V (formerly VLA15) (PFE). LNTH announced that FDA approved PET imaging agent Tauklarify for Alzheimer's Disease. The PDUFA goal date for MK-6240 was 16-Aug-2026. Note: Lantheus is pending acquisition by Curium US Research: CAPR upgraded to overweight from neutral at CF (Kristen Kluska), follows earnings call updates on BLA amendment. Target increased to $28 from $3.50 or approx. 565% upside. NERV upgraded to buy from hold at Jefferies (Andrew Tsai), target increased to $10 from $7.50 or approx. 155% upside. ALVO initiated outperform at Evercore ISI (Umer Raffat) KRYS initiated outperform at RBC (Lisa Walter), target is $400 or approx. 22% upside. (FactSet average PT $383; range $284-474) SGP initiated outperform at Raymond James (Christopher Raymond), target is $39 or approx. 55% upside. (FactSet average PT $45; range $37-62) Life Science & MedTech Research: FRNM initiated outperform at Leerink Partners (Puneet Souda), target is $18 or approx. 55% upside. On Deck: Aug 8 - 16 all clear Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Wed 19-Aug: Piper Sandler MedTech and Diagnostics California Bus Tour Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA (Note: Negative FDA Adcomm last month; optimistic mgmt comments on 13-Aug) Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALVO, BMY, BSX, CAPR, ETON, FRNM, HTFL, IPHA, KRYS, LLY, LNTH, NERV, PFE, RARE, SGP, SPRY, VALN, VERA, VLA.FP...(more)	show story hide story
14-Aug-2026 06:12	KRYS Krystal Biotech initiated outperform at RBC Capital Markets ($328.34) Target is $400, 22% upside (FactSet average target $382.86; range $284-474) Analyst is Lisa Walter	show story hide story
03-Aug-2026 16:43	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly lower overall on Monday. Advancers beat decliners by 2:1 on the XLV. Healthcare (0.17%) vs S&P 500 +1.48%. Little changed from the morning, as most major health groups end higher for the session. Pharma was the exception, large drugmakers mostly red (1%) to (2%), however the DRG (1.84%) remained skewed lower by AZN (6.9%) as investors reacted to the mega-merger headlines. BMY +0.2% finished at neither highs nor lows of the day. M&A dominated sector newsflow today, beginning with the potential for the largest pharma merger ever, if the media reports come to fruition. XBI +0.20% or essentially flat. Read-through for biotech cautious, as deal would remove one potential acquirer. BAX +7.4%, picking up where it left off last week, and MCK (3.4%) bracketed the XLV. MRNA +0.6% ahead of an imminent FDA decision on its influenza vaccine. Earnings calendar picks up tonight with VRTX (1.3%), followed by multiple large-cap drugmakers Tuesday morning. M&A Monday: FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring LNTH +1.6% for cash plus CVR valued at up to $8B combined. CNS drugmakers INDV (6.6%) and Supernus Pharma +3.1% will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Outside of pharma, ITGR +2.7% confirmed Friday's media report - KKR will acquire the CRO for $127/shr or $5.7B deal. Macro August started up with a risk-on session, helped by several tailwinds. Most Mag 7 names rallied sharply while some cyclical pockets fared well; momentum clawed off an early session selloff in the wake of last week's big rally. Market seemed to largely look past a day of conflicting headlines about the US-Iran conflict (Trump said attacks called off for negotiations, Iran said no negotiations ongoing), though continued escalate/deescalate cycle supportive of market's view that a return to broader kinetic action is unlikely. Today's lower oil also weighed on rates amid a continued flurry of Fed credibility concern/policy uncertainty headlines. Highest ISM manufacturing print in four years supportive of the solid macro narrative. Earnings still a big bullish talking point for stocks with the latest sell-side strategist commentary highlighting the strong Q2 metrics. Also a busy day of M&A headlines. Notable Gainers +12.1% SLS (SELLAS Life Sciences Group, Inc.): best performer on XBI; shares +198% YTD +11.0% HIMS (Hims & Hers Health): shares were down (20%) in July +10.4% TWST (Twist Bioscience): earnings; second-best on XBI +9.5% CDNA (CareDx): upgraded at Craig-Hallum +7.4% BAX (Baxter International): best performer on XLV; shares were +17% last week +7.2% ALNY (Alnylam Pharmaceuticals): upgraded at Raymond James +6.3% REPL (Replimune Group): follow-through, on >2X average volume; PDUFA was Sunday +6.2% ISRG (Intuitive Surgical): FDA 510(k) clearance for DV5 +4.8% SYK (Stryker): Medicare extends CJR-X model +3.6% BSX (Boston Scientific): Medicare extends CJR-X model +3.2% ZBH (Zimmer Biomet Holdings): Medicare extends CJR-X model +3.2% EW (Edwards Lifesciences): Medicare extends CJR-X model +3.1% SUPN (Supernus Pharmaceuticals): to merge with INDV; earnings +2.7% ITGR (Integer Holdings): confirms acquisition by KKR for $127/shr Notable Decliners -11.3% TGTX (TG Therapeutics): earnings; worst performer on XBI -8.4% KRYS (Krystal Biotech): earnings -7.4% SOBI.SS (Swedish Orphan Biovitrum): CEO to step down for outside opportunity -6.9% AZN (AstraZeneca): media report - in talks with BMY; takeaways -6.6% INDV (Indivior Pharmaceuticals): to merge with SUPN; earnings -3.4% MCK (McKesson): worst performer on XLV -2.7% DVA (DaVita): sympathy to FMS; second-worst on XLV -2.4% LLY (Eli Lilly): reports on Wednesday AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Actual M&A in biopharma LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B KKR takes Integer Holdings private in $5.7B deal ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Medicare extends CJR model as expected, althrough slightly delayed Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028 (vs proposed 1-Oct-2027) Gilead Sciences wins favorable ruling at California Supreme Court CA Supreme Court ruled 6-1 in favor of the HIV drugmaker, the TDF litigation put to rest a multi-decade legal overhang. Federal litigation was settled in 2024, but California went to trial, and lower courts had held Gilead Sciences (GILD) negligent for delaying development of a newer drug with fewer side effects than TDF. Notable research in Healthcare today Pharma: JNJ removed from the US Conviction List at Goldman Sachs. Biotech: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. MedTech: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Managed Care: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) Post-close news Earnings: VRTX reports Q2 EPS $4.73 vs FactSet $4.74 on revenue $3.33B vs FS $3.23B. Raises FY revenue outlook by $125M at the midpoints. Guidance does not incorporate pending acquisition of Crinetics Pharma (CRNX). Conf. call at 16:30ET Shares trading (0.3%) in the after-hours JAZZ reports Q2 EPS $5.71 ex-items vs FactSet $6.18 on revenue $1.21B vs FS $1.11B. Raises FY revenue outlook by $300M at the midpoints. Conf. call at 16:30ET Shares trading+4.4% in the after-hours CRSP reports Q2 results including cash & equivalents $2.36B as of 30-Jun. Casgevy $76M (sales reported by Vertex) +151% y/y growth. Shares trading +2.5% in the after-hours On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL TUDRIQEV (vusolimogene oderparepvec-wtpg) BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Earnings tomorrow before BAYN.GR (call at 8:00ET), MRK (call at 9:00ET), PFE (call at 10:00ET), IDXX (call at 8:30ET), WAT (call at 8:00ET), BNTX, SNN (call at 6:30ET), FMS (call at 8:00ET), RVTY (call at 7:30ET), HSIC (call at 8:00ET), BRKR (call at 9:00ET), RYTM (call at 8:00ET) after AMGN (call at 16:30ET), GILD (call at 16:30ET), DVA (call at 17:00ET), ARWR (call at 16:30ET), BIO (call at 17:00ET), PACS (call Wed at 11:30ET), TVTX (call at 16:30ET), ACAD (call at 16:30ET), HNGE (call at 16:30ET) Earnings on Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Corporate on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) StreetAccount Healthcare Reads How poor countries are dealing with America's AIDS cuts (3-Aug) The Economist Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea (3-Aug) Fierce Pharma (Opinion) AstraZeneca investors balk at prospect of $400 billion Bristol Myers deal (3-Aug) Reuters After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers (3-Aug) STAT News Kennedy, Oz Contend Fraud Crackdown, Not Skyrocketing Prices, Led Millions To Leave Obamacare (3-Aug) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, ADIL, ALHC, ALNY, AMGN, ARQT, ARWR, AZN, AZN.LN, BAX, BAYN.GR, BIO, BLLN, BMY, BNTX, BRKR, BSX, CAI, CDNA, CI, CLYM, COR, CRL, CRNX, CRSP, CVS, DVA, EHC, ELAN, EW, EXEL, FMS, FRE.GR, GILD, GRAL, HIMS, HNGE, HSIC, IDXX, INDV, ISRG, ITGR, JAZZ, JNJ, KRYS, KYMR, LIVN, LLY, LNTH, MCK, MDLN, MIRM, MRK, MRNA, NAMS, NVO, NVST, ONC, PACS, PFE, PODD, PYXS, QGEN, RCUS, REPL, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SLS, SNN, SOBI.SS, SOLV, STE, SUPN, SYK, TGTX, TVTX, TWST, UTHR, VRTX, WAT, YARW, ZBH...(more)	show story hide story
03-Aug-2026 10:13	KRYS Transcript Intelligence: Krystal Biotech Q2 Earnings Guidance ($311.51 -$29.61) Guidance Summary (Call Time: 03-Aug-26 08:30 ET): Nearer-term: Pricing negotiations in Germany complete by Q3 2026. Accrual impacts in Germany end by Q4 2026. Key pricing and reimbursement outcomes in Germany, Italy, and Spain before end of 2026. Penetration of diagnosed US DEB patient pool surpasses 60% target in coming quarters. KB801 EMERALD-1 study enrollment for neurotrophic keratitis complete by year-end 2026. KB407 cystic fibrosis study interim results from five patients before end of 2026. KB111 Hailey-Hailey disease study interim results from seven patients before year-end 2026. Alignment with FDA on KB407 cystic fibrosis registrational study design by end of 2026. Discussion with FDA on KB111 Hailey-Hailey disease safety results, scale, and study design before year-end 2026. Regulatory submissions for VYJUVEK in Switzerland and Australia in coming months. Non-GAAP R&D expenses 175M USD - 195M USD full-year 2026. Non-GAAP SG&A expenses 175M USD - 195M USD full-year 2026. Clinical updates on Gorlin syndrome patients treated with intratumoral KB707 later in 2026. Longer-term: Pricing and reimbursement discussions in France for VYJUVEK extend into 2027. KB407 cystic fibrosis registrational study start in 2027. KB111 Hailey-Hailey disease registrational study start in 2027. Inhaled KB707 second-line NSCLC registrational study initiation in 2027. BLA submission for KB803 in ocular DEB upon successful readout, leveraging VYJUVEK CMC work. KB801 EMERALD-1 study data readout and potential BLA filing in early 2027. Expand VYJUVEK access globally, aiming to reach thousands of patients in the years ahead. Transition into a multiproduct genetic medicines company within the next 12 to 18 months. Evaluate commercial opportunity for KB801 in NK, aiming for dominant market position post-approval. Leverage HSV-1 platform for additional indications in lungs, skin, and eye over the long term. This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 8/3/2026 10:13:16 AM - Transcript Intelligence: Krystal Biotech Q2 Earnings Themes 8/3/2026 10:13:16 AM - Transcript Intelligence: Krystal Biotech Q2 Earnings Q&A 8/3/2026 07:04:49 AM - Krystal Biotech reports Q2 EPS $1.85 vs FactSet $1.70 [10 est, $1.28-1.99] Reference Link: Transcript	show story hide story
03-Aug-2026 10:13	KRYS Transcript Intelligence: Krystal Biotech Q2 Earnings Themes ($312.63 -$28.49) Themes Summary (Call Time: 03-Aug-26 08:30 ET): Themes: Expand Global Access: Advance pricing, reimbursement, and regulatory submissions to broaden VYJUVEK’s reach internationally. Drive Community Engagement: Invest in patient education, peer support, and virtual programs to deepen market penetration and adherence. Advance Clinical Pipeline: Progress multiple registrational studies in rare diseases and oncology, targeting new indications and geographies. Navigating Market Dynamics: Manage country-specific launch challenges, including pricing negotiations and compliance requirements. Leverage Platform Versatility: Utilize HSV-1 vector technology for diverse applications across skin, lung, and eye diseases. Risks: Payer Negotiations: Uncertainty in international pricing/reimbursement could impact revenue predictability and patient access. Opportunities: Pipeline Expansion: Multiple upcoming registrational readouts offer potential for new product launches in large underserved markets. Strategic Adjustments: Pursue Global Trials: Shift to global study designs for key programs to enable simultaneous multi-region regulatory filings. This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 8/3/2026 10:13:16 AM - Transcript Intelligence: Krystal Biotech Q2 Earnings Q&A 8/3/2026 07:04:49 AM - Krystal Biotech reports Q2 EPS $1.85 vs FactSet $1.70 [10 est, $1.28-1.99] Reference Link: Transcript	show story hide story
03-Aug-2026 10:13	KRYS Transcript Intelligence: Krystal Biotech Q2 Earnings Q&A ($312.63 -$28.49) Q&A Summary (Call Time: 03-Aug-26 08:30 ET): Robust demand and patient inclusion observed in Europe and Japan, with strong compliance in Germany and France mirroring US trends. German pricing negotiations anticipated to conclude in Q3; accrual impact expected to normalize by Q4, returning to net revenue reporting. Hailey-Hailey Phase 1 data readout planned by year-end; registrational trial initiation targeted for early next year. NK (KB801) global trial enrollment completion projected by year-end; top-line data likely released early 2027, aiming for global filing. No upsizing of NK study planned; European site activation intended to accelerate recruitment without altering design or sample size. US VYJUVEK penetration surpassed initial targets, with ongoing opportunity among both RDEB and DDEB patients in community settings. European VYJUVEK sales increased sequentially on a gross pre-pricing accrual basis, though specific figures remain undisclosed but described as double-digit growth. This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 8/3/2026 07:04:49 AM - Krystal Biotech reports Q2 EPS $1.85 vs FactSet $1.70 [10 est, $1.28-1.99] Reference Link: Transcript	show story hide story
03-Aug-2026 09:15	StreetAccount Summary - US Pre-market trading update S&P futures +44.8 to 7564, +0.60% vs settlement. 10-year yield (3) bps to 4.68%. Sep WTI ($5.71) or (6.74%) to $78.96. Trading Higher: *Market cap >$10B* +10.0% CNH (CNH Industrial $11.28, +1.03) -- earnings +8.3% FERG (Ferguson Enterprises $253.75, +19.42) -- to join S&P 500 +6.6% WMG (Warner Music Group $27.67, +1.71) -- preliminary FQ3 results; CFO change +4.2% WDAY (Workday $167.00, +6.66) +4.0% HUBS (HubSpot $246.78, +9.42) +3.9% TEAM (Atlassian $105.00, +3.99) +3.9% OKTA (Okta, Inc. $147.44, +5.51) +3.9% BABA (Alibaba Group $126.96, +4.71) -- releases latest Qwen model +3.7% NOW (ServiceNow $115.40, +4.17) -- removed from Goldman Sachs US Conviction List - Directors' Cut +3.7% W (Wayfair $88.00, +3.10) +3.6% FSLR (First Solar $218.61, +7.58) +3.4% CRM (Salesforce $190.30, +6.28) +3.4% FTAI (FTAI Aviation Ltd. $212.98, +6.97) +3.2% IOT (Samsara $38.46, +1.19) +3.2% UAL (United Airlines $125.20, +3.87) -- oil lower +3.1% SHOP (Shopify $120.79, +3.64) +3.1% PANW (Palo Alto Networks $342.08, +10.25) +3.1% BMY (Bristol Myers Squibb $67.34, +2.03) -- AstraZeneca (AZN) reportedly in merger talks with Bristol Myers +3.1% DDOG (Datadog $276.40, +8.43) +3.0% SNOW (Snowflake $302.05, +8.77) +3.0% IBM (IBM $230.29, +6.64) +3.0% CTSH (Cognizant Technology Solutions $57.00, +1.65) +3.0% ADBE (Adobe $257.85, +7.44) +2.9% ACN (Accenture $170.75, +4.83) +2.9% ADSK (Autodesk $241.00, +6.80) -- completed previously announced acquisition of MaintainX Inc. +2.9% PLTR (Palantir Technologies $126.68, +3.62) -- partnership with Mercury Systems +2.8% INTU (Intuit $325.00, +8.93) +2.8% VEEV (Veeva Systems $209.55, +5.77) +2.8% CCL (Carnival $28.58, +0.77) -- oil lower +2.7% QXO (QXO, Inc. $13.66, +0.36) +2.7% FAST (Fastenal $49.00, +1.29) +2.7% LUV (Southwest Airlines $46.18, +1.21) -- oil lower +2.7% MDB (MongoDB $346.50, +9.02) +2.6% DOCU (DocuSign $56.27, +1.44) +2.6% CPRT (Copart $29.87, +0.75) +2.6% U (Unity Software $32.52, +0.81) +2.6% DAL (Delta Air Lines $89.67, +2.23) -- oil lower +2.6% L (Loews $119.00, +2.99) -- earnings +2.5% CRWD (CrowdStrike $195.70, +4.84) +2.5% RKT (Rocket Cos. $13.22, +0.32) +2.5% RBRK (Rubrik $74.15, +1.79) +2.4% BAX (Baxter International $26.80, +0.64) +2.4% VIK (Viking Holdings $106.89, +2.54) -- oil lower; added to Goldman Sachs US Conviction List - Directors' Cut +2.4% CRH (CRH plc $97.30, +2.29) +2.4% AMGN (Amgen $394.25, +9.09) +2.4% RCL (Royal Caribbean Group $325.99, +7.69) -- oil lower +2.3% BA (Boeing $221.08, +4.94) -- BNP Paribas Exane upgrade +2.3% TOST (Toast, Inc. $33.00, +0.73) +2.2% CLX (Clorox $97.63, +2.10) -- increases quarterly dividend by 0.8% to $1.25 from $1.24 +2.2% ORCL (Oracle $132.75, +2.88) +2.2% MCD (McDonald's $276.51, +5.87) +2.1% BNTX (BioNTech $92.50, +1.92) -- designated CEO Ugur Sahin steps down; appoints Guido Oelkers as new CEO from 1-Feb-27 +2.1% CVNA (Carvana $63.68, +1.32) +2.1% BKNG (Booking Holdings $196.95, +4.05) +2.1% GOOGL (Alphabet $363.56, +7.43) +2.1% MSFT (Microsoft $474.33, +9.61) -- added to Goldman Sachs US Conviction List - Directors' Cut +1.8% V (Visa $372.72, +6.59) -- to acquire BioCatch from funds advised by Permira and other shareholders for $2.4B in cash *Market cap $1B-$10B* +27.9% ATKR (Atkore $93.35, +20.39) -- Prysmian (PRY.IM) to acquire Atkore for $95/share in cash, or EV of $3.8B (€3.29B); earnings +14.1% SUPN (Supernus Pharmaceuticals $50.94, +6.31) -- Supernus Pharmaceuticals and Indivior Pharmaceuticals (INDV) announce all-stock merger of equals; earnings +10.3% BOW (Bowhead Specialty Holdings $33.75, +3.16) -- to be acquired by American Family Mutual Insurance Company for $34/sh; earnings +6.3% CDNA (CareDx $46.46, +2.75) -- Craig-Hallum upgrade +6.2% MMYT (MakeMyTrip $60.50, +3.55) -- earnings +5.6% AMC (AMC Entertainment $2.98, +0.16) -- announces record weekend revenue +5.3% TE (T1 Energy $4.39, +0.22) -- T1 and Clearway execute strategic offtake deal +4.1% MNDY (monday.com $90.75, +3.60) +4.1% NCNO (nCino $19.21, +0.75) +4.0% ULCC (Frontier Group $7.02, +0.27) -- oil lower +3.9% VERX (Vertex, Inc. $13.41, +0.50) +3.7% KVYO (Klaviyo $18.50, +0.66) +3.4% VFC (VF Corp $14.81, +0.49) -- insider buy +3.4% IMAX (Imax $49.47, +1.63) -- July global box office gross of $257M +3.3% TENB (Tenable Holdings $33.72, +1.08) +3.2% WIX (Wix.com $56.80, +1.77) +3.2% GTLB (Gitlab $35.60, +1.09) +3.2% AAL (American Airlines Group $15.76, +0.49) -- oil lower +3.1% ZETA (Zeta Global Holdings $22.28, +0.68) +3.1% ASAN (Asana, Inc. $8.58, +0.26) +3.1% CERT (Certara $8.35, +0.25) +3.1% FIVN (Five9 $28.35, +0.84) +3.1% CLBT (Cellebrite DI $15.20, +0.45) +3.0% ESTC (Elastic $67.76, +1.97) +3.0% MBGL (Mobility Global, Inc. $21.00, +0.62) +3.0% ABSI (Absci Corp. $8.01, +0.23) +2.9% LNTH (Lantheus Holdings $102.50, +2.86) -- to be acquired by Curium for $102.50/sh cash plus CVR for up to $12/sh in potential additional cash payments +2.7% ITGR (Integer Holdings $124.52, +3.31) -- confirms agreement to be acquired by KKR for $127/sh cash; earnings *Market cap <$1B* +12.1% AUTL (Autolus Therapeutics $1.67, +0.18) -- earnings; credit facility of up to $250M with Perceptive Advisors +11.7% FTK (Flotek Industries $26.29, +2.75) -- 10-year contract to support 400 MW power project for Puerto Rico electric power authority +9.1% PYXS (Pyxis Oncology $2.89, +0.24) -- Wells Fargo initiated overweight +6.1% CTKB (Cytek Biosciences $4.48, +0.26) +6.0% BIOA (BioAge Labs $9.58, +0.54) +5.2% SCTX (Scribe Therapeutics, Inc. $20.50, +1.02) +5.1% CERS (Cerus $2.26, +0.11) +4.4% ELDN (Eledon Pharmaceuticals $3.53, +0.15) +4.2% ZSQR (Z Squared, Inc. $5.01, +0.20) -- to acquire 100% of Paradox Data and Its Union County campus Trading Lower: *Market cap >$10B* -7.3% AZN (AstraZeneca $157.19, -12.45) -- reportedly in merger talks with Bristol Myers Squibb -6.2% KRYS (Krystal Biotech $320.01, -21.11) -- earnings -5.6% CRCL (Circle Internet $59.08, -3.53) -- Morgan Stanley downgrade -5.5% TSEM (Tower Semiconductor $207.49, -12.18) -4.4% WDC (Western Digital $520.63, -24.21) -4.3% STX (Seagate Technology $819.00, -37.13) -4.1% MU (Micron Technology $788.92, -34.11) -4.1% SMTC (Semtech $112.94, -4.88) -3.9% SNDK (Sandisk $1,167.58, -47.25) -3.7% TER (Teradyne $354.09, -13.60) -3.7% AMKR (Amkor Technology $48.00, -1.87) -- insider sale -3.7% VG (Venture Global $12.89, -0.49) -3.6% ALAB (Astera Labs $300.00, -11.23) -3.4% MRVL (Marvell Technology $181.14, -6.42) -3.3% ONTO (Onto Innovation $250.00, -8.58) -3.3% ANET (Arista Networks $174.45, -5.90) -3.3% KLAC (KLA $176.82, -6.00) -3.3% LITE (Lumentum Holdings $690.50, -23.44) -3.2% CRDO (Credo Technology $200.40, -6.59) -3.2% BE (Bloom Energy $199.24, -6.57) -3.1% TSN (Tyson Foods $56.15, -1.81) -- earnings -3.0% COHR (Coherent $254.96, -7.93) -2.7% EBAY (eBay $110.94, -3.07) -- Wells Fargo downgrade -2.7% LRCX (Lam Research $285.00, -8.02) -2.6% AMD (Advanced Micro Devices $463.85, -12.30) -2.6% RMBS (Rambus $88.68, -2.35) -2.6% ON (onsemi $79.47, -2.14) -2.5% CLS (Celestica $323.02, -8.42) -2.5% GFS (GlobalFoundries $48.75, -1.24) -2.5% AMAT (Applied Materials $495.00, -12.67) -2.5% MPWR (Monolithic Power Systems $1,390.00, -36.03) -2.5% NBIS (Nebius Group $185.58, -4.83) -2.4% MCHP (Microchip Technology $72.54, -1.75) -2.4% INTC (Intel $88.06, -2.14) -2.4% NXPI (NXP Semiconductors $223.67, -5.49) -- UBS downgrade -2.3% TTMI (TTM Technologies $112.75, -2.69) -2.3% NVMI (Nova Measuring Instruments $381.76, -9.11) -2.2% HUT (Hut 8 Corp. $105.31, -2.32) -2.1% DELL (Dell Technologies $397.00, -8.37) -2.1% MGM (MGM Resorts $43.63, -0.94) -2.1% MAR (Marriott International $364.85, -7.98) -- earnings -2.0% CBRS (Cerebras Systems $194.76, -3.95) -2.0% STRL (Sterling Infrastructure $585.00, -11.77) -2.0% LSCC (Lattice Semiconductor $121.75, -2.52) -2.0% CIEN (Ciena $369.59, -7.46) -1.9% ENTG (Entegris $116.74, -2.31) -1.9% BMNR (Bitmine Immersion Technologies $16.95, -0.33) -1.8% GLW (Corning $135.79, -2.46) -- Truist upgrade -1.6% SPCX (SpaceX $106.61, -1.76) *Market cap $1B-$10B* -18.3% SRAD (Sportradar Group $11.88, -2.66) -- earnings -6.4% KLIC (Kulicke & Soffa Industries $83.47, -5.73) -6.0% GME (GameStop $20.42, -1.30) -- private exchange of $1.4B of convertible senior notes for equity -6.0% TWST (Twist Bioscience $86.08, -5.47) -- earnings -5.2% AXTI (AXT Inc $57.28, -3.15) -4.5% GENI (Genius Sports $6.62, -0.31) -4.4% TGTX (TG Therapeutics $49.76, -2.27) -- earnings -4.4% ACMR (ACM Research $75.00, -3.47) -4.2% PLOW (Douglas Dynamics $42.28, -1.85) -- earnings -4.1% MXL (MaxLinear $64.11, -2.71) -4.1% SBH (Sally Beauty Holdings $14.35, -0.62) -- earnings -4.0% FORM (FormFactor $102.00, -4.20) -3.9% AEHR (Aehr Test Systems $76.89, -3.09) -3.7% AAOI (Applied Optoelectronics $90.80, -3.52) -3.6% SARO (StandardAero $28.25, -1.06) -3.4% PCOR (Procore Technologies $52.93, -1.85) -- proposed private placement of $750.0M of convertible senior notes due 2031 -3.4% VSH (Vishay Intertechnology $33.07, -1.15) -3.1% WOLF (Wolfspeed $22.88, -0.74) -3.0% AIP (Arteris $28.99, -0.89) -2.9% RYN (Rayonier $21.15, -0.63) -2.8% OUST (Ouster $37.93, -1.08) -2.6% VICR (Vicor $202.00, -5.37) *Market cap <$1B* -29.5% ZEO (Zeo Energy $0.35, -0.15) -23.1% CIGL (Concorde International Group $0.47, -0.14) -- recent IPO -11.9% HKIT (Hitek Global $2.67, -0.36) -10.3% PN (Skycorp Solar Group $15.49, -1.78) -6.4% SPRY (ARS Pharmaceuticals $4.80, -0.33) -3.8% FBIO (Fortress Biotech $3.01, -0.12) -3.2% MRAM (Everspin Technologies $14.06, -0.47) -3.2% SGMT (Sagimet Biosciences $6.88, -0.23) Oil/energy related lower -- WTI futures (6.6%) after Trump calls off Iran strikes KOS -9.0% (earnings), WTI -5.3%, SOC -3.6%, OBE -3.5%, VET -3.4%, MUR -3.3%, SM -3.2%, PBF -3.2%, BP -2.9%, EQNR -2.6%, WDS -2.5%, APA -2.5%, OXY -2.5%, PARR -2.4%, OVV -2.4%, NOG -2.4%, CRGY -2.4%, RIG -2.3%, PR -2.3%, CVE -2.3%, FANG -2.2%, NEXT -2.2%, DVN -2.1%, PBR -2.0%, CRK -2.0%, BORR -2.0%, COP -2.0%, CNQ -1.9%, SU -1.9%, AR -1.8%, EOG -1.8%, CVX -1.6%, XOM -1.6%, YPF -1.6%, DINO -1.6%, VLO -1.6%, SHEL -1.5%, HAL -1.3%, LNG -1.2%, MPC -1.2%, MTDR -0.8% Click here to view our Gainers & Decliners page Editor's Note: This comment was revised to clarify that NOW was removed from Goldman's US Conviction List, not added (03-Aug-2026, 09:28 ET) Related: AAL, AAOI, ABSI, ACMR, ACN, ADBE, ADSK, AEHR, AIP, ALAB, AMAT, AMC, AMD, AMGN, AMKR, ANET, APA, AR, ASAN, ATKR, AUTL, AXTI, AZN, BA, BABA, BAX, BE, BIOA, BKNG, BMNR, BMY, BNTX, BORR, BOW, BP, CBRS, CCL, CDNA, CERS, CERT, CIEN, CIGL, CLBT, CLS, CLX, CNH, CNQ, COHR, COP, CPRT, CRCL, CRDO, CRGY, CRH, CRK, CRM, CRWD, CTKB, CTSH, CUK, CVE, CVNA, CVX, DAL, DDOG, DELL, DINO, DOCU, DVN, EBAY, ELDN, ENTG, EOG, EQNR, ESTC, FANG, FAST, FBIO, FERG, FIVN, FORM, FSLR, FTAI, FTK, GENI, GFS, GLW, GME, GOOGL, GTLB, HAL, HKIT, HUBS, HUT, IBM, IMAX, INTC, INTU, IOT, ITGR, KLAC, KLIC, KOS, KRYS, KVYO, L, LITE, LNG, LNTH, LRCX, LSCC, LUV, MAR, MBGL, MCD, MCHP, MDB, MGM, MMYT, MNDY, MPC, MPWR, MRAM, MRVL, MSFT, MTDR, MU, MUR, MXL, NBIS, NCNO, NEXT, NOG, NOW, NVMI, NXPI, OBE, OKTA, ON, ONTO, ORCL, OUST, OVV, OXY, PANW, PARR, PBF, PBR, PCOR, PLOW, PLTR, PN, PR, PYXS, QXO, RBRK, RCL, RIG, RKT, RMBS, RYN, SARO, SBH, SCTX, SGMT, SHEL, SHOP, SM, SMTC, SNDK, SNOW, SOC, SPCX, SPRY, SRAD, STRL, STX, SU, SUPN, TE, TEAM, TENB, TER, TGTX, TOST, TSEM, TSN, TTMI, TWST, U, UAL, ULCC, V, VEEV, VERX, VET, VFC, VG, VICR, VIK, VLO, VSH, W, WDAY, WDC, WDS, WIX, WMG, WOLF, WTI, XOM, YPF, ZEO, ZETA, ZSQR...(more)	show story hide story
03-Aug-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis M&A Monday with the potential for the largest pharma merger ever, if the media reports come to fruition. FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Shares of BMY +4% in the pre-market; AZN (6%) in the pre-market. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring Lantheus for cash plus CVR valued at up to $8.0B combined. Shares of LNTH +3% in the pre-market. CNS drugmakers Indivior ($4.8B) and Supernus Pharma ($2.5B) will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Shares of INDV +3% and SUPN +15% in the pre-market. Integer Holdings confirms the media report on Friday, KKR will acquire the CRO for $127/shr or $5.7B deal. Shares of ITGR +3% in the pre-market. Macro S&P futures are up +0.5% on Monday morning. Risk sentiment underpinned by renewed traction surrounding escalate to de-escalate narrative as Trump said over the weekend he called off a potential attack on Iran to allow for more talks, which he noted will take place on Monday. Also reports Iran and Oman nearing a deal regarding a new SoH route. Pretty quiet outside of geopolitics. Strength of Q2 earnings season and positive revisions the big theme in recent strategist commentary. Open-weight still the big story in AI with focus on new Qwen3.8-Max model. Fed credibility another high-profile theme with Musalem flagging signaling from bond market. US and Japan confirmed joint intervention to support yen and warned more could be in the pipeline. Big M&A in the weekend headlines with report about potential tie-up in pharma. Pre-market trading update Trading higher +15.4% SUPN to merge with INDV; earnings +4.9% CDNA upgraded at Craig-Hallum +4.1% BMY media report - AZN merger talks; takeaways +3.0% INDV to merge with SUPN; earnings +2.9% LNTH acquired by Curium for cash + CVR +2.7% ITGR confirms acquisition by KKR for $127/shr +2.7% VEEV Wells Fargo comments on impact from AZN-BMY Trading lower -7.9% KRYS earnings -7.2% TWST earnings -6.4% SOBI.SS in European trading; CEO to step down for outside opportunity -6.1% AZN media report - in talks with BMY; takeaways -5.5% TGTX earnings -2.5% REPL follow-through; PDUFA was Sunday -2.3% ABVX sympathy to pharma M&A headlines Pharma M&A: AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Regulatory: NOVN.SW (NVS) FDA approves Pluvicto sNDA for metastatic hormone-sensitive prostate cancer (mHSPC). PDUFA was expected during H2 of 2026. Research: JNJ removed from the US Conviction List at Goldman Sachs. Biotech M&A: LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B Conf. call at 8:30ET Research: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. Life Science & MedTech M&A: ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Research: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Services & Hospitals Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Managed Care Research: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL vuso-vec BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva BLA Corporate JNJ hosting business update call to discuss recent FDA approval of OTTAVA Robotic Surgery System (8:00ET) MRK hosting business update call post-International AIDS Conference (8:00ET) on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) Earnings after the close today: VRTX (call at 16:30ET), JAZZ (call at 16:30ET) Earnings tomorrow Tue 4-Aug: before BAYN.GR, MRK, PFE, IDXX, WAT, BNTX, SNN, FMS, RVTY, HSIC, BRKR, RYTM after AMGN, GILD, DVA, ARWR, BIO, PACS, TVTX, ACAD, HNGE This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABVX, ACAD, ADIL, ALHC, ALNY, AMGN, ARWR, AZN, AZN.LN, BAYN.GR, BIO, BMY, BNTX, BRKR, CDNA, CI, CLYM, DVA, FMS, GILD, HNGE, HSIC, IDXX, INDV, ITGR, JAZZ, JNJ, KRYS, LNTH, MRK, MRNA, NAMS, NOVN.SW, PACS, PFE, PYXS, REPL, RVTY, RYTM, SNN, SOBI.SS, SUPN, TGTX, TVTX, TWST, VRTX, WAT, YARW...(more)	show story hide story
03-Aug-2026 08:21	StreetAccount Summary - US Pre-market trading S&P futures +35.8 to 7555, +0.48% vs settlement. 10-year yield (4) bps to 4.67%. Sep WTI ($5.65) or (6.67%) to $79.02. Trading Higher: *Market cap >$10B* +7.9% FERG (Ferguson Enterprises $252.96, +18.63) -- to join S&P 500 +7.7% CNH (CNH Industrial $11.04, +0.79) -- earnings +4.5% BMY (Bristol Myers Squibb $68.24, +2.93) -- AstraZeneca (AZN) in talks with Bristol Myers Squibb - media reports +4.1% TEAM (Atlassian $105.17, +4.16) +4.0% BABA (Alibaba Group $127.10, +4.85) -- Alibaba releases latest Qwen model +3.6% HUBS (HubSpot $246.00, +8.64) +3.4% OKTA (Okta, Inc. $146.72, +4.79) +3.3% SNOW (Snowflake $303.00, +9.72) +3.2% NOW (ServiceNow $114.81, +3.58) +3.2% DOCU (DocuSign $56.58, +1.75) +3.2% WDAY (Workday $165.44, +5.10) +3.2% FSLR (First Solar $217.75, +6.72) +3.0% ADBE (Adobe $258.00, +7.59) +2.9% CRM (Salesforce $189.34, +5.32) +2.8% PANW (Palo Alto Networks $341.28, +9.45) +2.8% IOT (Samsara $38.30, +1.03) +2.7% ACN (Accenture $170.38, +4.46) +2.7% INTU (Intuit $324.50, +8.43) +2.7% GEN (Gen Digital $28.20, +0.75) +2.6% L (Loews $119.00, +2.99) -- earnings +2.6% SHOP (Shopify $120.17, +3.02) +2.6% ADSK (Autodesk $240.35, +6.15) +2.5% UAL (United Airlines $124.40, +3.07) -- oil lower +2.5% CTSH (Cognizant Technology Solutions $56.74, +1.39) +2.5% W (Wayfair $87.00, +2.10) +2.4% VEEV (Veeva Systems $208.61, +4.83) +2.4% CDNS (Cadence Design Systems $348.34, +8.32) +2.4% DDOG (Datadog $274.46, +6.49) +2.4% PLTR (Palantir Technologies $126.07, +3.01) +2.4% QXO (QXO, Inc. $13.62, +0.32) +2.4% MDB (MongoDB $345.51, +8.03) +2.3% CRWD (CrowdStrike $195.20, +4.34) +2.3% RBRK (Rubrik $74.01, +1.65) +2.3% APP (AppLovin $405.00, +9.10) +2.2% ORCL (Oracle $132.69, +2.82) +2.1% U (Unity Software $32.37, +0.66) +2.1% ZTS (Zoetis $78.91, +1.62) +2.1% AAL (American Airlines Group $15.59, +0.32) -- oil lower +2.1% META (Meta Platforms $568.45, +11.74) +2.1% FIG (Figma $24.82, +0.50) +2.0% IBM (IBM $228.10, +4.45) +2.0% TTWO (Take-Two Interactive $247.76, +4.84) +2.0% ZS (Zscaler $154.20, +3.00) +2.0% APTV (Aptiv Plc $57.59, +1.12) +2.0% CCL (Carnival $28.36, +0.55) +2.0% SNPS (Synopsys $396.50, +7.74) +2.0% LUV (Southwest Airlines $45.85, +0.88) -- oil lower +2.0% TOST (Toast, Inc. $32.90, +0.63) +1.9% BA (Boeing $220.30, +4.16) -- BNP Paribas Exane upgrade +1.9% MSFT (Microsoft $473.44, +8.72) +1.9% MCD (McDonald's $275.71, +5.07) *Market cap $1B-$10B* +28.1% ATKR (Atkore $93.47, +20.51) -- Prysmian (PRY.IM) to acquire Atkore for $95/share in cash, or EV of $3.8B (€3.29B); earnings +15.8% SUPN (Supernus Pharmaceuticals $51.67, +7.04) -- Supernus Pharmaceuticals and Indivior Pharmaceuticals (INDV) announce all-stock merger of equals; earnings +9.2% BOW (Bowhead Specialty Holdings $33.41, +2.82) -- to be acquired by American Family Mutual Insurance Company for $34/sh; earnings +6.7% AMC (AMC Entertainment $3.01, +0.19) -- announces record weekend revenue +6.0% CDNA (CareDx $46.35, +2.64) -- Craig-Hallum upgrade +5.3% TE (T1 Energy $4.39, +0.22) -- T1 and Clearway execute strategic offtake deal +4.5% MMYT (MakeMyTrip $59.50, +2.55) -- earnings +4.1% BILL (Bill Holdings $47.00, +1.87) +4.0% FIVN (Five9 $28.62, +1.11) +3.8% KVYO (Klaviyo $18.51, +0.67) +3.5% ABSI (Absci Corp. $8.05, +0.27) +3.1% ESTC (Elastic $67.85, +2.06) +3.1% SAIL (SailPoint $17.29, +0.52) +3.1% PAYC (Paycom Software $168.97, +5.01) +2.9% GTLB (Gitlab $35.51, +1.00) +2.9% WIX (Wix.com $56.62, +1.59) +2.9% ALM (Almonty Industries $11.38, +0.32) +2.8% SDGR (Schrödinger $15.57, +0.43) +2.8% LNTH (Lantheus Holdings $102.40, +2.76) -- to be acquired by Curium for $102.50/sh cash plus CVR for up to $12/sh in potential additional cash payments +2.7% VERX (Vertex, Inc. $13.26, +0.35) +2.7% QGEN (Qiagen $42.52, +1.12) +2.7% ZETA (Zeta Global Holdings $22.18, +0.58) +2.7% PCT (Purecycle Technologies $6.54, +0.17) +2.6% ASAN (Asana, Inc. $8.54, +0.22) +2.6% PATH (UiPath $13.10, +0.34) +2.6% ITGR (Integer Holdings $124.40, +3.19) -- confirms agreement to be acquired by KKR for $127/sh cash; earnings +2.6% VFC (VF Corp $14.70, +0.38) -- insider buy +2.5% FMC (FMC Corp $10.98, +0.27) +2.5% MNDY (monday.com $89.31, +2.16) +2.5% ALK (Alaska Air Group $48.65, +1.20) +2.4% NOMD (Nomad Foods $12.19, +0.29) +2.4% INDV (Indivior Pharmaceuticals $40.97, +0.96) -- Supernus Pharmaceuticals SUPN) and Indivior Pharmaceuticals announce all-stock merger of equals +2.4% AVPT (AvePoint $13.34, +0.31) +2.4% KD (Kyndryl Holdings $13.87, +0.32) *Market cap <$1B* +32.6% DFNS (T3 Defense $36.71, +9.03) +8.7% PYXS (Pyxis Oncology $2.88, +0.23) -- Wells Fargo initiated overweight +8.6% PUSA (Aureus Greenway Holdings, Inc. $3.28, +0.26) +7.7% FTK (Flotek Industries $25.35, +1.81) -- 10-year contract to support 400 MW power project for Puerto Rico electric power authority +6.9% INTT (inTEST $13.21, +0.86) -- Northland Capital Markets upgrade +6.5% CERS (Cerus $2.29, +0.14) +6.0% BIOA (BioAge Labs $9.58, +0.54) +5.4% GRO (Brazil Potash $2.15, +0.11) +5.3% TSSI (TSS Inc $10.45, +0.53) +5.3% OCS (Oculis Holding $11.91, +0.60) -- FDA provides Oculis Holding feedback on Privosegtor to treat acute MS relapses +5.2% NEOV (NeoVolta $2.22, +0.11) +5.1% TENX (Tenax Therapeutics $14.40, +0.70) +3.7% TLRY (Tilray Brands $4.71, +0.17) +3.6% VYGR (Voyager Therapeutics $3.14, +0.11) +3.6% PD (PagerDuty $10.96, +0.38) Trading Lower: *Market cap >$10B* -8.4% KRYS (Krystal Biotech $312.37, -28.75) -- earnings -6.1% CRCL (Circle Internet $58.80, -3.81) -- Morgan Stanley downgrade -5.3% TSEM (Tower Semiconductor $208.00, -11.67) -5.3% AZN (AstraZeneca $160.63, -9.01) -- AstraZeneca in merger talks with Bristol Myers Squibb - media reports -4.5% SMTC (Semtech $112.50, -5.32) -4.2% AMKR (Amkor Technology $47.80, -2.07) -- insider sale -4.1% SNDK (Sandisk $1,165.43, -49.40) -4.0% ALAB (Astera Labs $298.78, -12.45) -4.0% MU (Micron Technology $790.00, -33.03) -3.7% WDC (Western Digital $524.50, -20.34) -3.7% BE (Bloom Energy $198.20, -7.61) -3.6% MAR (Marriott International $359.45, -13.38) -- earnings -3.5% EBAY (eBay $110.00, -4.01) -- Wells Fargo downgrade -3.4% STX (Seagate Technology $827.00, -29.13) -3.4% VG (Venture Global $12.93, -0.45) -3.0% COHR (Coherent $255.02, -7.87) -3.0% ANET (Arista Networks $175.00, -5.35) -3.0% TSN (Tyson Foods $56.20, -1.76) -- earnings -3.0% ONTO (Onto Innovation $250.82, -7.76) -- awarded $15.0M USAF contract -2.9% MRVL (Marvell Technology $182.20, -5.36) -2.8% NXPI (NXP Semiconductors $222.70, -6.46) -- UBS downgrade -2.8% LRCX (Lam Research $284.89, -8.13) -2.7% CRDO (Credo Technology $201.40, -5.59) -2.7% KLAC (KLA $177.85, -4.97) -2.7% TER (Teradyne $357.77, -9.92) -2.6% AMAT (Applied Materials $494.26, -13.41) -2.5% INTC (Intel $87.97, -2.23) -2.5% ON (onsemi $79.57, -2.04) -2.4% LITE (Lumentum Holdings $696.85, -17.09) -2.4% BMNR (Bitmine Immersion Technologies $16.86, -0.42) -2.4% MGM (MGM Resorts $43.52, -1.05) -2.4% TTMI (TTM Technologies $112.70, -2.74) -2.3% FLEX (Flex $111.17, -2.58) -2.3% MTSI (MACOM Technology $245.64, -5.80) -2.3% WMG (Warner Music Group $25.36, -0.60) -- CFO/COO Armin Zerza steps down for personal reasons, effective 31-Jul -2.3% MPWR (Monolithic Power Systems $1,392.76, -33.27) -2.3% AMD (Advanced Micro Devices $465.00, -11.15) -0.3% ECHO (EchoStar $83.87, -0.22) -- earnings *Market cap $1B-$10B* -18.6% SRAD (Sportradar Group $11.83, -2.71) -- earnings -8.2% GME (GameStop $19.93, -1.79) -- private exchange of $1.4B of convertible senior notes for equity -6.0% TWST (Twist Bioscience $86.10, -5.45) -- earnings -5.4% TGTX (TG Therapeutics $49.20, -2.83) -- earnings -5.1% AXTI (AXT Inc $57.34, -3.09) -5.0% AEHR (Aehr Test Systems $76.01, -3.97) -4.7% ACMR (ACM Research $74.81, -3.66) -4.5% MXL (MaxLinear $63.79, -3.03) -4.1% PLOW (Douglas Dynamics $42.34, -1.79) -- earnings -3.5% SHAZ (SharonAI Holdings $46.55, -1.70) -3.5% VSH (Vishay Intertechnology $33.01, -1.21) -3.4% AAOI (Applied Optoelectronics $91.11, -3.21) -3.4% VECO (Veeco Instruments $48.32, -1.68) -3.4% ALGM (Allegro MicroSystems $40.10, -1.40) -3.3% RMBS (Rambus $88.00, -3.03) -3.2% FORM (FormFactor $102.84, -3.36) -3.2% PENG (Penguin Solutions $50.96, -1.67) -3.2% COHU (Cohu $46.45, -1.54) -3.1% WOLF (Wolfspeed $22.88, -0.74) -3.0% VICR (Vicor $201.17, -6.20) *Market cap <$1B* -29.1% ZEO (Zeo Energy $0.35, -0.15) -19.0% CIGL (Concorde International Group $0.50, -0.12) -- recent IPO -8.6% PN (Skycorp Solar Group $15.78, -1.49) -8.4% SKYQ (Sky Quarry $4.26, -0.39) -4.9% EGG (Enigmatig $3.47, -0.18) -4.7% FBIO (Fortress Biotech $2.98, -0.15) -4.5% SPRY (ARS Pharmaceuticals $4.90, -0.23) -4.1% FNKO (Funko, Inc. $5.59, -0.24) *Oil/energy related lower; WTI futures (6.83%)* KOS -6.3% (earnings), WTI -5.0%, OBE -3.9%, SM -3.0%, MTDR -2.5%, PBF -2.4%, PARR -2.3%, CRGY -2.2%, VET -2.2%, NOG -2.2%, PUMP -2.1%, APA -2.0%, PR -1.9%, NEXT -1.9%, EOG -1.8%, SU -1.8%, CVE -1.7%, OXY -1.7%, COP -1.6%, OVV -1.6%, DVN -1.6%, VLO -1.6%, DINO -1.5%, FANG -1.4%, CNQ -1.4%, HESM +2.4% (earnings) Click here to view our Gainers & Decliners page Related: AAL, AAOI, ABSI, ACMR, ACN, ADBE, ADSK, AEHR, ALAB, ALGM, ALK, ALM, AMAT, AMC, AMD, AMKR, ANET, APA, APP, APTV, ASAN, ATKR, AVPT, AXTI, AZN, BA, BABA, BE, BILL, BIOA, BMNR, BMY, BOW, CCL, CDNA, CDNS, CERS, CIGL, CNH, CNQ, COHR, COHU, COP, CRCL, CRDO, CRGY, CRM, CRWD, CTSH, CUK, CVE, DDOG, DFNS, DINO, DOCU, DVN, EBAY, ECHO, EGG, EOG, ESTC, FANG, FBIO, FERG, FIG, FIVN, FLEX, FMC, FNKO, FORM, FSLR, FTK, GEN, GME, GRO, GTLB, HESM, HUBS, IBM, INDV, INTC, INTT, INTU, IOT, ITGR, KD, KLAC, KOS, KRYS, KVYO, L, LITE, LNTH, LRCX, LUV, MAR, MCD, MDB, META, MGM, MMYT, MNDY, MPWR, MRVL, MSFT, MTDR, MTSI, MU, MXL, NEOV, NEXT, NOG, NOMD, NOW, NXPI, OBE, OCS, OKTA, ON, ONTO, ORCL, OVV, OXY, PANW, PARR, PATH, PAYC, PBF, PCT, PD, PENG, PLOW, PLTR, PN, PR, PUMP, PUSA, PYXS, QGEN, QXO, RBRK, RMBS, SAIL, SDGR, SHAZ, SHOP, SKYQ, SM, SMTC, SNDK, SNOW, SNPS, SPRY, SRAD, STX, SU, SUPN, TE, TEAM, TENX, TER, TGT, TGTX, TLRY, TOST, TSEM, TSN, TSSI, TTMI, TTWO, TWST, U, UAL, VECO, VEEV, VERX, VET, VFC, VG, VICR, VLO, VSH, VYGR, W, WDAY, WDC, WIX, WMG, WOLF, WTI, ZEO, ZETA, ZS, ZTS...(more)	show story hide story
03-Aug-2026 07:04	KRYS Krystal Biotech reports Q2 EPS $1.85 vs FactSet $1.70 [10 est, $1.28-1.99] ($341.12) Reports Q2: Revenue (all VYJUVEK net product revenue) $119.2M vs FactSet $120.9M [10 est, $118-124.9M] R&D expense $14.5M vs FactSet $17.7M Cash, cash equivalents and investments totaled $1.1B as of 30-Jun-26 FY Guidance (Dec 2026): Reaffirms R&D and SG&A expense $175.0-195.0M VYJUVEK Updates The company has secured over 730 reimbursement approvals for VYJUVEK and, as of the end of 2Q 2026, had expanded the VYJUVEK prescriber base to include over 640 unique prescribers. The company is advancing pricing and reimbursement discussions across Europe. Pricing discussions with German and French reimbursement authorities remain ongoing and are expected to continue until at least 2H 2026 in Germany and into 2027 in France. Pricing discussions in Italy and Spain are also progressing and the company continues to expect commercial launches in both countries before year end. Pricing discussions in the UK are now underway. The company expects to file multiple additional marketing authorization applications for VYJUVEK in 2H 2026, including in Switzerland and Australia. Reference Link: Press release	show story hide story
31-Jul-2026 21:36	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed and moderately lower overall on Friday. At the close, decliners just outnumbered advancers on the XLV, breadth significantly improved from the morning session. Healthcare (0.55%) vs S&P 500 +0.70%. All major health groups lagged the wider tape, and most ended red on the session. Services group today's relative performer, including UHS +3.2% among top performers on the XLV. Declines moderated in the afternoon session, only the XBI (2.94%) significantly lower on the day, followed by DRG (0.95%). Biotech returns were market-cap agnostic. Daily double for REPL +107.0% on favorable FDA Adcom outcome. DRG (1.65%) with NVO (8.8%) on late-stage setback for IL-6 program with read-across negative into SMID-cap biotech. Large-cap drugmakers end mixed on the session, including ABBV (2.5%) following the Q2 print. A pair of medical device names bracketed the XLV on respective earnings updates, DXCM +12.0% and SYK (6.4%). TNDM +2.6% but other diabetes tech names unable to keep pace. Stryker's soft outlook reading across cautiously to LC ortho peers. Hospitals were the only notable pockets of strength today. Macro: Lots of moving pieces to end a busy week. Momentum better again on the back of a big Thursday bounce, though not a one-way trade despite latest flurry of deleveraging done/cleaner positioning chatter. Hyperscaler capex ROI momentum in focus for a second straight session with the blowout AWS results (and AI/chip business momentum) from AMZN. However, also a flurry of big earnings decliners today, including AAPL on softer Sep Q guidance chalked up to supply chain and input cost pressures. Renewed backup in yields the other big story, though no one specific catalyst (FOMC dissent details, more Warsh credibility headlines, BoJ and yen intervention dynamics, higher oil). Combination of momentum outperformance and higher yields may be acting as overhangs on the broadening out trade (with technicals also recently flagged). Today marks month-end (momentum unwind the big story for July) and August represents one of the worst months from a seasonal perspective (though buybacks pick up throughout the month). Next week brings another big week of earnings (~14% of S&P 500 market cap) and high-profile July macro data. Notable Gainers on Friday: +107.0% REPL (Replimune Group): FDA panel recommends vuso-vec; upgrade; best performer on XBI +56.3% APMD (Apnimed): day one IPO (biotech) +20.2% ITGR (Integer Holdings): media report, in talks to be acquired by KKR +14.7% CDNA (CareDx): earnings +13.4% IRWD (Ironwood Pharmaceuticals): sympathy to AbbVie (Linzess); best one-day return in six months +12.0% DXCM (Dexcom): earnings; best performer on XLV +6.3% GH (Guardant Health): earnings Notable Decliners on Friday: -72.6% KPTI (Karyopharm Therapeutics): trial results in endometrial cancer; downgrades -63.6% BIOA (BioAge Labs): sympathy to NVO -46.7% MYGN (Myriad Genetics): earnings; worst performer on XBI -27.2% GLUE (Monte Rosa Therapeutics): sympathy to NVO -22.5% VCYT (Veracyte): earnings -20.2% ALHC (Alignment Healthcare): earnings -13.2% IOVA (Iovance Biotherapeutics): sympathy to REPL -10.1% NBIX (Neurocrine Biosciences): earnings -9.9% PTCT (PTC Therapeutics): earnings -8.8% NVO (Novo Nordisk): trial results with IL-6 in MACE reductions -6.4% SYK (Stryker): earnings; worst performer on XLV -5.4% MRNA (Moderna): earnings Week in Review: Earnings scorecard: According to FactSet Scorecard, with 35.54% of companies (59 of 166) having reported, 94.92% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +12.67% vs +8.67% last year. On the topline, 93.22% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +2.94% vs +2.56% last year. Healthcare equities underperformed for the week. The S&P 500 Healthcare Index essentially flat (0.01%) vs the S&P 500 Index higher +1.05%. Outperformers: MedTech, Services Underperformers: Managed Care, Biotech, Pharma Major health groups were widely mixed around the tape this week. Earnings calendar the primary source of newsflow with key reports from all corners of the sector. Strong earnings combined with upgraded outlooks lifted most equipment stocks, despite the setup from HCA's recent warning. Obesity duopoly weighed by Cigna commentary on GLP-1s, and Novo Nordisk diversification strategy took a hit after ZEUS trial failure. JNJ proposed a $5.5B settlement to resolve MDL talc litigation. FDA Adcoms are back - and the REPL case a good reminder why. The same committee agreed with FDA on the CAPR case. Biotech returns driven more this week by earnings than M&A. Year-to-date, Healthcare +4.86% vs the S&P 500 +9.41%. Healthcare seventh out of eleven major sectors in CY26. Energy +32.77% and Consumer Discretionary (0.31%) bracket them all. Notable movers for the week: Gainers: TRAX +24.0% - best performer on XBI; follow-through, shares +119% for the month AVTR +20.5% - earnings; upgraded at Jefferies CORT +20.1% - earnings; Lifyorli launch KNSA +18.3% - earnings; raised guidance for Arcalyst BAX +16.8% - earnings; upgraded at Citi; best performer on XLV DXCM +16.6% - earnings; raised guidance REGN +16.3% - earnings; Dupixent beat REPL +15.5% - FDA briefing documents (negative); FDA Adcom (positive) MMSI +14.4% - earnings; raised guidance TEVA +13.6% - earnings; sympathy to ALVO site inspection IQV +13.0% - earnings; raised guidance GEHC +12.3% - earnings; reaffirmed GH +10.0% - earnings SOLV +9.5% - assumed buy at UBS (upgrade) THC +9.3% - follows +20% prior week; sympathy to UHS RGEN +6.9% - earnings Decliners: CAPR (80.5%) - FDA briefing documents / FDA Adcom (negative); worst performer on XBI ALNY (24.4%) - earnings; lowers guidance for Amvuttra ALHC (23.6%) - earnings; guidance VCYT (18.2%) - earnings LEGN (16.5%) - CEO steps down to pursue outside opportunity MDGL (14.2%) - earnings HUM (6.5%) - earnings; 3 upgrades & 1 downgrade; worst performer on XLV WAY (6.2%) - earnings; CFO departs for personal reasons Week Ahead (Sat - Sun): Aug 1 - 9 Regulatory calendar Sun 2-Aug: FDA PDUFA for REPL vuso-vec BLA Wed 5-Aug: FDA PDUFA for MRNA mFlusiva BLA Corporate calendar Mon 3-Aug: JNJ hosting business update call to discuss recent FDA approval of OTTAVA Robotic Surgery System (8:00ET); MRK hosting business update call post-International AIDS Conference (8:00ET) Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) Earnings calendar Mon 3-Aug: before 4523.JP, KRYS, TGTX, TWST after VRTX, JAZZ Tue 4-Aug: before BAYN.GR, MRK, PFE, IDXX, WAT, BNTX, SNN, FMS, RVTY, HSIC, BRKR, RYTM, INDV after AMGN, GILD, DVA, ARWR, BIO, PACS, TVTX, ACAD, HNGE Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, ITGR, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI Conference calendar n/a Syndicate calendar / potential IPO pricing n/a Related: 4523.JP, ABBV, ACAD, ALHC, ALNY, ALVO, AMGN, APMD, ARQT, ARWR, AVTR, BAX, BAYN.GR, BDX, BIO, BIOA, BLLN, BMRN, BNTX, BRKR, CAI, CAPR, CDNA, CON, COR, CORT, CRL, CVS, CYTK, DFTX, DNLI, DVA, DXCM, EHC, ELAN, EXEL, FMS, FRE.GR, GEHC, GH, GILD, GLUE, GMAB, GMED, GRAL, HAE, HALO, HNGE, HSIC, HUM, ICUI, IDXX, IMVT, INDV, INSM, IOVA, IQV, IRTC, IRWD, ITGR, JAZZ, JNJ, KNSA, KPTI, KRYS, KYMR, LEGN, LFST, LGND, LIVN, LLY, LNTH, MCK, MDGL, MDLN, MIRM, MMSI, MRK, MRK.GR, MRNA, MYGN, NAMS, NBIX, NTRA, NVO, NVST, ONC, OSCR, PACS, PFE, PODD, PRAX, PRVA, PTCT, QGEN, RCUS, REGN, REPL, RGEN, RLAY, RMD, ROIV, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SHC, SNN, SOLV, SRRK, STE, SYK, TEVA, TFX, TGTX, THC, TRAX, TVTX, TWST, TXG, UHS, UTHR, VCYT, VRTX, VTRS, WAT, WAY, XENE, ZBH, ZTS...(more)	show story hide story
21-Jul-2026 17:31	KRYS Krystal Biotech provides update on KB801 patent and trademark filing - 8-K ($339.06) On 21-Jul-26, Krystal Biotech, Inc. filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801 In support of the patentability of the claims, the response included data from a patient who received KB801 in a discontinued clinical study and experienced complete closure of a persistent corneal epithelial defect. The company discontinued the clinical study in order to advance KB801 into a pivotal trial and no safety concerns or serious adverse events were observed in patients treated in the study. Reference Link: 8-K filing	show story hide story
21-Jul-2026 08:36	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar returns with two key reports this morning: Danaher and Novartis. Danaher reports Q2 beat with core growth improvement sequentially, but focus is on the forward guide with top-end of FY core growth dialed back. Bioprocessing segment missed in Q2 and Q3 guided down. Shares of DHR (12%) in the pre-market, and bioprocessing peers down MSD, diversified LifeSci peers down LSD. Novartis reports Q2 beat and reaffirmed FY guidance. Also on track for H2 readouts. No specific mention of pelacarsen. ADRs trading +3% higher in the pre-market. SMID-cap biotech Agio Pharma announced topline results from midstage trial with tebapivat for sickle cell disease. Study did not substantially perform on the primary endpoint, and the company decided not to advance further. Shares of AGIO down (14%) in the pre-market. Macro S&P futures are up +0.5% on Tuesday morning. Momentum making another bounce attempt. Nothing specific behind the move. Some focus on magnitude of the unwind, cleaner (though still elevated) positioning, along with a looming pickup in earnings activity that could help put the focus back on the compute/capex demand narrative. Semis expected to account for nearly half of S&P 500 earnings growth in Q2. Market continues to largely ignore geopolitics as ceasefire hopes seem to be overshadowing elevated kinetic hostilities and worries about heightened supply disruptions. Trump's 50% tariffs on select Canadian goods, China's push to boost stock market, potential China crackdown on export of AI technologies and return of $4 per gallon gasoline in the US also in the headlines. Pre-market trading update Trading higher +5.6% NAMS initiation +3.0% NVS earnings; call at 8ET +2.6% AHCO divestiture; upgraded at Jefferies Trading lower -13.9% AGIO trial results in sickle cell disease -12.0% DHR earnings; call at 8ET -9.3% RGEN sympathy to DHR -3.9% BIO sympathy to DHR -3.3% A sympathy to DHR -3.3% BRKR sympathy to DHR -3.1% TMO sympathy to DHR -2.8% AVTR sympathy to DHR -0.9% GILD downgraded at Leerink -0.9% NVO sues LLY over misleading ads -0.6% LLY sued by NVO over misleading ads; tirzepatide generic challengers Pharma Earnings: NOVN.SW (NVS) reports Q2 core EPS $2.41 vs consensus $2.15 on revenue $14.41B vs consensus $13.95B. Company remains on track to deliver FY guidance and mid-term outlook, also affirms on track for H2 readouts. No specific mention of pelacarsen in the PR. Conf. call at 8:00ET Corporate / litigation: Eli Lilly (LLY) sued by Novo Nordisk (NOVO.B.DC, NVO) over its DTC advertising for Zepbound and Mounjaro, claiming it omits relevant information about the most effective injectable doses of Wegovy and Ozempic. Regulatory: LLY FDA discloses initial Paragraph IV certifications filed for various doses of Zepbound and Mounjaro. More than a dozen generic challengers filed ANDAs. Research: BHC transferred hold at Jefferies (Young Li), target is $5.50 vs prior $6 or approx. 18% upside. (FactSet average PT $8; range $7-9) Biotech Trial results: AGIO announced topline results from its phase 2 trial evaluating tebapivat in sickle cell disease. Study did not substantially perform on the primary endpoint, and the company has decided not to advance further. Index changes: KRYS added to the S&P MidCap 400 Index, removed from the SmallCap 600 Index. Research: GILD downgraded to market perform from outperform at Leerink Partners (Daina Graybosch). Firm sees long-term headwinds to HIV prophylaxis market expansion. Target cut to $127 from $146 or approx. 5% downside. (FactSet average PT $161; range $120-180) ACAD transferred outperform at BMO Capital Markets (Malcolm Hoffman), target increased to $36 from $34 or approx. 43% upside. (FactSet average PT $33; range $17-45) ANNX initiated market underperform at Citizens (Jonathan Wolleben), target is $3 or approx. 46% downside. (FactSet average PT $15; range $7-27) AXSM initiated outperform at BMO Capital Markets (Malcolm Hoffman), target is $310 or approx. 40% upside. (FactSet average PT $279; range $242-380) ELDN initiated buy at Rodman & Renshaw (Seema Sheoran), target is $12 or approx. 211% upside. (FactSet average PT $9; range $7-12) FBRX initiated overweight at Barclays (Etzer Darout), target is $74 or approx. 56% upside. (FactSet average PT $67; range $54-75) INSM initiated outperform at BMO Capital Markets (Conor MacKay), target is $192 or approx. 79% upside. (FactSet average PT $196; range $140-243) LBRX initiated outperform at BMO Capital Markets (Malcolm Hoffman), target is $46 or approx. 49% upside. (FactSet average PT $45; range $34-78) LGND resumed buy at Citi (Yigal Nochomovitz), target increased to $387 from $282 or approx. 32% upside. (FactSet average PT $216; range $247-399) MPLT initiated outperform at BMO Capital Markets (Malcolm Hoffman), target is $46 or approx. 28% upside. (FactSet average PT $42; range $30-60) NAMS initiated outperform at BMO Capital Markets (Conor MacKay), target is $58 or approx. 95% upside. (FactSet average PT $52; range $38-60) TRVI initiated outperform at BMO Capital Markets (Conor MacKay), target is $36 or approx. 115% upside. (FactSet average PT $26; range $20-40) Life Science & MedTech Earnings: DHR reports Q2 EPS $1.94 ex-items vs FactSet $1.84 on revenue $6.27B vs FS $6.11B. Core revenue grew +3.0% y/y. Guides Q3 core revenue growth +2.0-3.0%. Lowers FY core revenue growth outlook to +3-4% vs prior +3-6%. Quick Take: Share declines are attributed to weaker-than-expected bioprocess results and lowered Q3 core revenue guidance, with the implied Q4 acceleration viewed as challenging. Discussion also views the bioprocessing slowdown as difficult to reconcile given the otherwise positive trends across the broader bioprocessing market. However, some remain constructive, citing strong bioprocessing order trends and viewing the guidance as attainable. Conf. call at 8:00ET Research: KMTS initiated perform at Oppenheimer (Suraj Kalia) Services & Hospitals Media report / activist: CHE Bloomberg reporting that activist holder Barington Capital Group is pushing for board changes, a strategic review, and cost cuts. Corporate: AHCO announced the divestiture of its Diabetes Health business to CAH for $235M in cash. Research: AHCO upgraded to buy from hold at Jefferies (Brian Tanquilut), noting improved growth/earnings visibility as a result of the Diabetes divestiture. On Deck: Earnings tomorrow afternoon: MOH (call Thu at 8:00ET), MEDP (call Thu at 9:00ET), CYH (call Thu at 11:00ET) Earnings on Thu 23-Jul: before ROP.SW (call at 8:00ET), SRT3.GR (call at 7:00ET), DGX (call at 8:30ET), TMO (call at 8:30ET), WST (call at 8:00ET) after EW (call at 17:00ET), SMMT (call at 16:30ET) Regulatory (cont.): EMA CHMP monthly meeting (Jul 20-23) on Thu 23-Jul: FDA advisory committee: Compounding Drugs to discuss peptides (Jul 23-24) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ACAD, AGIO, AHCO, ANNX, AVTR, AXSM, BHC, BIO, BRKR, CAH, CHE, CYH, DGX, DHR, ELDN, EW, FBRX, GILD, INSM, KMTS, KRYS, LBRX, LGND, LLY, MEDP, MOH, MPLT, NAMS, NOVN.SW, NOVO.B.DC, NVO, NVS, RGEN, ROP.SW, SMMT, SRT3.GR, TMO, TRVI, WST...(more)	show story hide story
20-Jul-2026 17:45	S&P discloses Krystal Biotech KRYS will replace TMHC in S&P MidCap 400, effective 24-Jul Tudor Perini Corp TPC will replace KRYS in the S&P SmallCap 600, effective 24-Jul due to Berkshire Hathaway acquisition of TMHC expected to close soon. Separately, V2X VVX will replace Avanos Medical AVNS in the S&P SmallCap 600, effective 27-Jul, as American Industrial Partners is acquiring AVNS Editor's note: this comment was edited to correct typo in first bullet Related: AVNS, BRK.B, KRYS, TMHC, TPC, VVX...(more)	show story hide story

Download StreetAccount for iOS from the App Store.
All times are in (UTC-05:00) Eastern Time (US & Canada) unless otherwise specified.
Copyright ©2026 FactSet Research Systems Inc.

Terms and Conditions Disclaimer Sitemap Privacy Policy Careers

during 2026		Interim data from repeat-dose Cohort 2B of the Phase 1 SERPENTINE-1 study in patients with AATD--with a PiZZ or a PiZNull genotype KB408
by the end of 2026		Data from EMERALD-1 registrational study evaluating KB801 for the treatment of NK KB801
by the end of 2026		Topline results from Phase 3 IOLITE registrational study--corneal abrasions in Dystrophic Epidermolysis Bullosa (DEB) KB803
Hide Additional Events

Week \| Month \| Quarter
Start:
End:
Enter dates in mm/dd/yyyy format